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1 Introduction 
1.1 Rationale and objectives of this work 
Degenerative aortic stenosis (AS) is the most common severe valvular heart disease in the elderly 
with an estimated prevalence of 2.8-5% in individuals above an age of 75 years (Nkomo, V. T. et 
al. 2006, Lindroos, M. et al. 1993). Thus, the prevalence of degenerative AS is strongly linked to 
the phenomenon of population ageing. According to the United Nations 2008 Population Database 
(United Nations Population Division 2008), by 2050, the number of people older than 80 years in 
developed countries will have increased by +227% from 53 million today to 120 million. As the 
age of the Western population increases, AS will become more frequent and is expected to repre-
sent an increasingly important public health burden (Vahanian, A. et al. 2007). Currently, each year 
more than 21,000 aortic heart valve operations are performed in Germany (Table 3), thereof over 
40% in patients older than 70 years (Gummert, J. F. et al. 2008). The total number of these inter-
ventions has grown steadily in recent years and is expected to further increase, particularly in elder-
ly patients (Gummert, J. F. et al. 2008). 
The natural course of symptomatic severe AS is dismal with high mortality rates. The 3-year sur-
vival in the untreated course of patients with AS is only 25% in comparison to a matched popula-
tion with 77% (O'Keefe, J. H., JR et al. 1987). After the onset of heart failure, median survival is 
only 11 months, after onset of syncope and angina 27 months and 45 months, respectively 
(Horstkotte, D. and Loogen, F. 1988). Because of the high risk of restenosis, balloon aortic val-
vuloplasty (BAV) can only be considered as a palliative treatment method for patients with a good 
quality of life (QoL) who are not eligible for surgical aortic valve replacement (AVR) (Figulla, H. 
R. et al. 2009, Carabello, B. A. and Paulus, W. J. 2009). Currently, surgical AVR is regarded to be 
the mainstay for improved survival and symptom relief, even in elderly patients (Varadarajan, P. et 
al. 2006b, Bouma, B. J. et al. 1999).  
However, the European Heart Survey of patients with valvular heart disease suggests that up to 
33% of patients over the age of 75 years are not considered for surgical AVR because of age and 
comorbidities (Iung, B. et al. 2005). An emerging less invasive treatment – transcatheter aortic 
valve implantation (TAVI) – promises effective treatment for high-risk patients not suitable for 
surgical AVR. As of today, TAVI is intended as a treatment alternative to “no intervention” for in-
operable patients. The initial successful report of a TAVI intervention for AS in a patient with a 
cardiogenic shock was reported by Cribier and colleagues in 2002 (Cribier, A. et al. 2002). Since 
then, various devices were introduced and evaluated with promising clinical results. Recently, larg-
er studies have demonstrated that TAVI can be performed in these patients with reasonably low 
mortality rates (Rodés-Cabau, J. et al. 2010). As of today, approximately 20,000 TAVI procedures 
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have been performed worldwide – and this number experiences exponential growth (communica-
tion with TAVI devices manufacturers in June 2010). However, the adoption of TAVI must be justi-
fied and guarantee long-term performance. If TAVI outcomes can fulfill these expectations, the 
technology will have a strong impact not only on the number of treatable patients, but also on the 
division of work between clinical departments. In the past, effective therapy of AS had been exclu-
sively performed by cardiac surgeons. With the development of TAVI, cardiologists have gained 
ground in the effective treatment of AS because TAVI requires hybrid procedures and joint patient 
selection. Regardless the narrow definition of the eligible TAVI patient population, the statistics 
from Table 3 are well suited to trigger speculations to which extent TAVI will replace traditional 
heart surgery in the future. 
Systematic reviews are core to formal decision making processes in evidence-based health econom-
ics (Drummond, M. F. et al. 2007). They apply a series of methodological principles which aim at 
systematically identifying, evaluating and summarizing all available data to provide objective evi-
dence for judging medical effectiveness. To date, few systematic reviews on the safety and efficacy 
of TAVI procedures have been conducted, but none of them have focused on 1-year follow-up data 
nor have earlier reviews conducted a comparison with recent evidence on medical therapy. There-
fore, the objectives of this work are firstly, to objectively assess the safety and efficacy of TAVI at 
30-day and 1-year follow-up, and secondly, to assess whether TAVI confers a survival benefit in 
patients with symptomatic severe AS when compared with patients potentially eligible for TAVI 
who did not receive an intervention – either they refused or were turned down – and continue with 
medical therapy. 
 
1.2 Brief overview aortic stenosis (AS) 
1.2.1 Clinical background, incidence and natural history 
The aortic valve acts as a gateway for the flow of blood between the left ventricle and the aorta. 
During systole (the period of left ventricular contraction), the aortic valve opens and allows blood 
to flow from the left ventricle to the aorta towards the body. During diastole (the period of left ven-
tricular filling) the aortic valve closes, preventing the backflow of blood to the heart, and the left 
ventricle is filled with blood arriving from the lungs through the left atrium across the mitral valve. 
In patients with AS, a narrowing of the aortic valve opening creates increased resistance to the flow 
of blood from the left ventricle to the aorta, thus increasing the afterload of the left ventricle. This 
may lead to symptoms, such as angina pectoris, syncope, dyspnoea, or heart failure, and in symp-
tomatic patients with a severe stenosis, to sudden death. In case of aortic regurgitation (AR), the 
aortic valve leaks every time the left ventricle relaxes, allowing blood to flow backwards from the 
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aorta into the left ventricle. The amount of regurgitation can be estimated by echocardiography. The 
backflow of blood causes overloading and dilatation of the left ventricle and may lead to symptoms 
and to irreversible damage to the left ventricle and heart failure (Carabello, B. A. and Paulus, W. J. 
2009). AS can mostly be suspected clinically and diagnosis is confirmed by echocardiographic 
examination and Doppler which enables to assess the severity of the stenosis and its consequences 
on the left ventricle. An aortic valve opening <1.0 cm² and a mean transaortic gradient >40 mmHg 
indicate severe AS (Bonow, R. O. et al. 2006, Iung, B. et al. 2003).  
AS is the most common severe valvular heart disease in Western countries. In the Euro Heart Sur-
vey, AS constituted 46.5% of all valvular heart disease identified in a population of 5,001 (Iung, B. 
et al. 2003). Of 1,197 cases of AS screened in several academic and non-academic centers from 25 
countries, 81.9% were degenerative, 11.2% rheumatic, 5.4% congenital, and 0.8% due to endocar-
ditis (Iung, B. et al. 2003). In a population-based study, hemodynamically significant AS affected 
2.8% of the general population ≥ 75 years of age (Nkomo, V. T. et al. 2006).  
Development of severe symptoms of AS remains the major demarcation point in the natural history 
of AS (Bonow, R. O. et al. 2006, Ross, J., JR. and Braunwald, E. 1968). The asymptomatic patient 
has a good outlook even with severe obstruction, but once symptoms occur, there is a sudden in-
crease in mortality rate in the ensuing years (Carabello, B. A. and Paulus, W. J. 2009). According to 
some authors, average survival after onset of symptoms is 2 to 3 years (Ross, J., JR. and Braun-
wald, E. 1968). These claims originate from work published in the late 1960s, but controlled trials 
comparing conservative medical therapy with surgical aortic AVR have never been performed. 
Over time, the primary etiology of AS in Western countries has changed from rheumatic to senile 
degeneration resulting from a progressive age-dependent build-up of calcium. Today’s patient pop-
ulation is older and has more associated comorbidities, such as coronary artery disease. Thus, it 
seems questionable whether the results of earlier studies on the natural history of AS can be gener-
alized in respect to today’s patient population. The natural history of AS nowadays and the impact 
of valvular correction, especially in the elderly, is not well known and may be different from the 
often cited historic data from Ross and Braunwald, obtained from clinical and postmortem studies 
in an era when the age at the time of clinical presentation averaged 48 years and echocardiography 
had not yet been introduced into clinical practice (Ross, J., JR. and Braunwald, E. 1968). However, 
even in a more recent study, the median survival in elderly patients with severe AS and symptomat-
ic heart failure was only 13 months (Aronow, W. S. et al. 1993).  
 
 11 
1.2.2 Treatment options and their limitations 
1.2.2.1 Medical therapy 
Recent studies have indicated that AS is caused by an active inflammatory process similar to that of 
atherosclerosis (Carabello, B. A. and Paulus, W. J. 2009). Thus, treatments for slowing down pro-
gression of coronary disease, most notably statins, have been investigated for similar effects in 
patients with AS. Findings of several retrospective studies showed that patients receiving statins 
had a slower progression of AS than patients not receiving them (Rajamannan, N. M. 2004). How-
ever, an important randomized controlled trial (RCT) of patients with moderate AS, could not re-
port survival benefits from statin use (Cowell, S. J. et al. 2005). Contrary, Moura and colleagues 
(Moura, L. M. et al. 2007) reported significantly slower progression of AS for patients with mild 
disease. Other medical treatment is exclusively directed towards symptoms such as diuretics in 
fluid retentions. From these results one can conclude, that presently available medical therapy can 
only result in a temporary alleviation of symptoms but curing AS requires replacement of the ste-
nosed valve.  
1.2.2.2 Surgical aortic valve replacement (AVR) 
The surgical therapy with prosthetic replacement of the aortic valve is considered the gold standard 
for treatment of symptomatic AS (Bonow, R. O. et al. 2006). Surgical AVR allows access to the 
stenosed aortic valve through a median sternotomy or minimal-invasive opening of the chest and 
the aorta. This surgical procedure always requires the use of a heart-lung machine with the associ-
ated risks. Current guidelines on the management of valvular heart disease (Bonow, R. O. et al. 
2006, Vahanian, A. et al. 2007) recommend surgical AVR for symptomatic patients even in the very 
elderly as increased perioperative mortality rates appear to be acceptable compared to the natural 
history of valvular heart disease. In particular, these risks are accepted because previous studies 
have not only reported significant survival benefits but also improvement of NYHA functional 
class (Varadarajan, P. et al. 2006b) and QoL (Sundt, T. M. et al. 2000, Olsson, M. et al. 1996) even 
for octogenarians. However, this recommendation from guidelines applies only as long as the pa-
tients have no severe comorbidities, which increase the risk of the procedure disproportionately. 
For this reason, a high proportion (33%-41%) of patients who might benefit from surgical AVR is 
rejected by surgeons or rejects the procedure (Iung, B. et al. 2005, Bouma, B. J. et al. 1999). 
1.2.2.3 Balloon aortic valvuloplasty (BAV) 
BAV has been introduced in the 1980s as a non-surgical treatment alternative for inoperable pa-
tients with symptomatic severe AS. BAV consists in stretching and cracking the stenosed aortic 
valve by means of an inflating balloon in an attempt to reduce the degree of stenosis. The technique 
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has shown to provide temporary improvement of valvular function and relief of symptoms in inop-
erable patients (Letac, B. et al. 1989, Eltchaninoff, H. et al. 1995). However, its use was diminished 
by an unacceptably high early restenosis rate and lacking mortality benefits (Lieberman, E. B. et al. 
1995, Letac, B. et al. 1991). Therefore, BAV is only considered as a palliative treatment option 
today (Figulla, H. R. et al. 2009, Eltchaninoff, H. et al. 2000). However, with the advent of TAVI, 
there has been a resurgence of interest in BAV procedures in bridging patients to TAVI (Kapadia, S. 
R. et al. 2009, Sack, S. et al. 2008).  
1.2.2.4 Transcatheter aortic valve implantation (TAVI) 
The above described traditional treatment options are challenged by an emerging non-surgical 
method of AVR which has revived interest in the management of severely ill patients. The concept 
of transcatheter insertion of an aortic valve was first performed by Cribier, A. et al. 2002. Initially, 
TAVI insertion was completed via an antegrade approach, indicating that the catheter was advanced 
along the direction of the blood flow. Because of potential complications at the level of the mitral 
valve, this approach has been replaced by the retrograde (transvascular (TV)) approach. This tech-
nique, however, can be impeded due to difficulties to advance large catheter through frail femoral 
or iliac arteries encountered in elderly patients. These difficulties led to the development of the 
transapical (TA) approach requiring a mini-thoracotomy for delivery of the device via the cardiac 
apex of the left ventricle. Due to the patient selection process illustrated in Figure 1, patients treated 
by the TA route mostly have a higher risk profile than patients treated by the TV approach. Howev-
er, the feasibility of TAVI does not only depend on the vascular accessibility, but also on the anat-
omy of the ascending aorta and the aortic annulus. Therefore, correct sizing of the valve is critical 
to minimize potential for post-procedural prosthesis migration and paravalvular leakage (Vahanian, 
A. et al. 2007). 
Several types of TAVI systems are currently tested at various stages of development. For the time 
being, two systems have received CE-marking required for clinical use and are in scope of this 
work: firstly, the Edwards SAPIEN® system (Edwards Life Sciences, Inc.), a balloon-expandable 
transcatheter aortic valve which consists of 3 pericardial bovine leaflets mounted within a tubular, 
slotted, stainless steel balloon-expandable stent. Both insertion techniques (TV and TA access) are 
commonly used for the Edwards system. The second system - the self-expandable Medtronic 
CoreValve® system (Medtronic CoreValve, LLC) - consists of 3 pericardial tissue porcine leaflets, 
mounted and sutured in a self-expandable nitinol stent. The current CoreValve device was further 
redesigned in the fixing of the valve tissue onto the stent, decreasing the profile to 18F sheaths; the 
CoreValve system is delivered via the TV route. 
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Until a convincing evidence base from long-term and randomized studies becomes available, TAVI 
should only be considered in inoperable or very high risk patients such as patients with a very high 
estimated surgical risk or of old age and with a degenerated bioprosthesis or porcelain aorta. Ac-
cording to existing evidence, only patients with an expected operative mortality of >10% (which 
corresponds to a logistic EuroSCORE >20% or to a STS score >10%) should be eligible for TAVI 
(Figulla, H. R. et al. 2009). 
European (Vahanian, A. et al. 2008, Figulla, H. R. et al. 2009) and American (Bonow, R. O. et al. 
2006) guidelines recommend that a careful TAVI patient evaluation involving a joint decision by 
multidisciplinary teams of interventional cardiologists, cardiothoracic surgeons, and cardiac anes-
thesiologists is needed to avoid the risk of uncontrolled diffusion of the TAVI technique. The ex-
perts also warn against extending the technique to lower-risk patients, given the low mortality rates 
achieved by surgical AVR. 
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2 Methods 
2.1 Systematic review of TAVI 
2.1.1 Inclusion and exclusion criteria 
This systematic review was based on published clinical case series and cohort studies as well as 
published secondary literature, such as systematic reviews and health technology assessments 
(HTAs) either published in peer-reviewed scientific journals or published by known HTA institutes. 
Only primary publications that met the criteria listed in Table 4 were eligible for consideration. 
Unpublished study results presented at international conferences were excluded because of the 
difficulty in appraising methodology. Characteristics of included patient populations were defined 
in accordance with the most recent German positioning statement on TAVI patient selection (Fig-
ulla, H. R. et al. 2009).  
For secondary publications, inclusion requirements were a matching thematic focus along with a 
detailed documentation of the included primary literature, the period during which the literature 
search was conducted, the applied search strategy, and the databases used.  
 
2.1.2 Data sources, selection, extraction and evaluation of information 
2.1.2.1 Data sources for peer-reviewed publications 
Peer-reviewed literature searches were conducted for the clinical review on March 4, 2010. The 
bibliographic databases MEDLINE, EMBASE Ovid, Centre for Reviews and Dissemination 
(CRD), and Cochrane Library were searched. The search strategy consisted of controlled vocabu-
lary, such as the National Library of Medicine’s MeSH (Medical Subject Headings) terms, and free 
text keywords. The main search concepts were “aortic valve” OR “aortic valve stenosis” AND 
“percutaneous” OR “transcatheter” OR “transvascular” OR “transapical”. The detailed search strat-
egy is provided in the Appendix 7.6. The search was not restricted to any publication period, but to 
English and German language and an adult patient population. EMBASE and MEDLINE Au-
toAlerts were set-up to send monthly updates with new literature until April 30, 2010. An internet 
search using Google Advanced Search was also conducted. These searches were supplemented by 
hand searching the reference lists of key papers for further identification of potentially relevant 
studies and through contacts with appropriate experts. No limitation was included on the study 
type, and therefore, identification of systematic reviews and cost-effectiveness data was combined 
within the above search strategy. 
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2.1.2.2 Data sources for publications from health technology institutes 
In order to find HTAs and systematic reviews on TAVI previously published by health technology 
institutes, the Centre for Reviews and Dissemination (CRD), Cochrane Database of Systematic 
Reviews (CDSR), and International Network of Agencies for Health Technology Assessment 
(INAHTA) electronic databases were searched on March 4, 2010. The MeSH terms “aortic steno-
sis” AND “heart valve prosthesis” were used to identify potentially relevant publications. In addi-
tion, the databases of major HTA institutes (Deutsche Agentur für Health Technology Assessment 
(DAHTA), Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), and Nation-
al Institute for Health and Clinical Excellence (NICE)) were consulted for further references on the 
above keywords. The reference lists of all retrieved secondary reports were reviewed for further 
identification of potentially relevant publications. 
2.1.2.3 Data selection and extraction 
The references resulting from the literature search were exported into a literature database (Citavi 
2.5.2.0). Literature selection was conducted in three stages: an initial screening of titles and ab-
stracts against the inclusion criteria defined in Table 4 to identify potentially relevant reports fol-
lowed by screening of the full text publications identified as possibly relevant. The data from the 
remaining reports was extracted and evaluated again against selection criteria to identify the rele-
vant reports to be included into the literature review. For all reports that were excluded based on 
extracted data, the rationale for exclusion was recorded (Table 1). 
A structured Microsoft Excel data extraction form was used to extract the following data from each 
study: 
 Study characteristics: number of patients, enrollment period, study center, study design, valve 
type, TAVI approach, duration of follow-up 
 Patient characteristics: age, gender, estimated operative risk, New York Heart Association 
(NYHA) functional class, baseline echocardiographic data (transaortic mean/ peak gradient, 
aortic valve area (AVA), left ventricular ejection fraction (LVEF)) 
 Primary outcome measures (safety): procedural success rate, complications, mortality, survival 
 Secondary outcome measures (efficacy): post-procedural echocardiographic data, NYHA func-
tional class, length of hospital stay, QoL, cost-effectiveness 
In the Appendix 7.5/ Table 17, the extracted data from all included primary publications on TAVI is 
provided. 
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2.1.2.4 Evaluation and synthesis  
The methodological quality of identified primary publications was evaluated using the checklist 
#2a for primary studies published by the German Scientific Working Group Technology Assess-
ment for Health Care (GSWG) (German Scientific Working Group for Health Care 2000c). 
Secondary publications were assessed along the checklists #1b for systematic reviews/ meta-
analyses and #1a for context documents/ HTAs which were also developed by the GSWG (German 
Scientific Working Group for Health Care 2000b, 2000a). 
For the qualitative information synthesis of primary publications, a structured Microsoft Excel 
reporting template was developed that summarized the study design, methodological approach, 
patient characteristics, and primary and secondary outcome measures for each included study (Ap-
pendix 7.5/ Table 17). 
The information synthesis of included secondary publications, describing the institutional back-
ground, objectives, methodological approach, results, and conclusions, was conducted for each of 
the recent secondary publications1 in chapter 3.1.3. 
 
2.1.3 Statistical methods 
Categorical or binary variables are expressed as percentages (absolute number of patients (n); 
range). Metric variables are expressed as (mean (range))all included studies/ (mean±standard deviation 
(SD))subset studies reporting SD.  
Except for the number of patients, only aggregated statistics (study means and SD) were available 
from primary publications. Means were calculated based on all included studies and, to ensure con-
sistent analysis of study characteristics, based on the subset of those studies reporting the SD. With 
few exceptions, deviations between means based on all included studies and means of the subset of 
studies reporting SD were small, and no significant mean difference was found. In conclusion, it is 
reasonable to regard those SD as representative for all studies. Where SD were reported, the overall 
SD was calculated as the square root of the mean of variances plus the variance of means. With the 
exception of number of patients, specified ranges refer to extreme values of reported study means, 
not to extreme values of raw data which were not available.  
                                                     
1 For earlier secondary publications which are already captured in the systematic review of the Bel-
gian Health Care Knowledge Center (KCE) (van Brabandt, H. and Neyt, M. 2008), only a tabular-
ized overview and a summary of conclusion is provided in chapter 3.1.3. 
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The estimation of 95%-confidence intervals (CI) for survival rates relied on the normal approxima-
tion to the binomial distribution.  
Significance tests were conducted to compare baseline data, and, if data for both subgroups was 
available, procedural and outcome results of TV-TAVI versus TA-TAVI2. All significance tests were 
two-sided. For metric variables, which were assumed normal, homogeneity of variance was first 
tested with the F-test. Mean difference was tested with the t-test for independent groups if the p-
value was greater than the significance level α=0.05. Otherwise the Welch-test was chosen as the 
appropriate test. Binary and categorical variables were compared assuming the null hypothesis of 
equal distribution within the two groups, i.e. observed and expected counts were calculated, and the 
Chi-square (χ2)-test was performed on the contingency tables. The null hypothesis of equal means 
or equal distributions respectively, was rejected if the p-value was smaller than or equal the signifi-
cance level α=0.05. 
Data collection and statistical analysis were performed using Microsoft Excel. 
 
2.2 Systematic review on medical therapy of AS 
2.2.1 Inclusion and exclusion criteria 
Only published peer-reviewed clinical cohort studies that met the inclusion criteria listed in Table 5 
were considered for the information synthesis on medical therapy of AS. The characteristics of 
included patient populations were defined in accordance with the preceding review on TAVI in 
chapter 2.  
 
2.2.2 Data sources, selection, extraction and evaluation of information 
2.2.2.1 Data sources 
For the review on medical therapy of AS, a peer-reviewed literature search analogous to the search 
described in detail in chapter 2.1.2.1 was conducted on March 4, 2010. Findings in EMBASE and 
MEDLINE were updated until April 30, 2010. The search strategy consisted of controlled vocabu-
lary, including The National Library of Medicine’s MeSH terms, and free text keywords, such as 
                                                     
2 These comparisons should only be assessed in conjunction with the described baseline differences 
between the respective patient groups. 
 18 
“aortic valve stenosis” AND “natural history” OR “medical therapy” OR “conservative treatment”. 
The detailed search strategy is provided in the Appendix 7.6.  
2.2.2.2 Data selection and extraction 
The references resulting from the literature search were exported into a literature database (Citavi 
2.5.2.0). Data selection was conducted in two stages: an initial screening of titles and abstracts 
against the selection criteria in Table 5 to identify potentially relevant reports followed by a de-
tailed screening of the full-text publications identified as possibly relevant in the initial screening. 
For all reports that were excluded based on the full-text screening, the rationale for exclusion was 
recorded (Table 2).  
A structured Microsoft Excel data extraction form was used to extract the following data from each 
included study: 
 Study characteristics: number of patients, enrollment period, study center, study design, inter-
vention of treatment cohorts, duration of follow-up 
 Patient characteristics: age, gender, estimated operative risk, NYHA functional class, baseline 
echocardiographic data (transaortic mean/ peak gradient, AVA, LVEF) 
 Primary outcome measures (safety): complications, mortality, survival 
In the Appendix 7.5/ Table 18, the extracted data from all included primary publications on medical 
therapy of AS is provided. 
2.2.2.3 Evaluation and Synthesis 
The methodological quality of identified studies was evaluated using the checklist #2a for primary 
studies of the GSWG (German Scientific Working Group for Health Care 2000c). 
For the qualitative information synthesis of primary publications, a structured Microsoft Excel 
reporting template was developed that summarized the study design, methodological approach, 
patient characteristics, and primary and secondary outcome measures for each included study. The 
template and extracted data are provided in the Appendix 7.5/ Table 18. 
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2.2.3 Statistical methods 
The statistical methods applied for the evaluation of extracted data for this review were identical to 
those described in chapter 2.1.3. 
Significance tests were conducted to compare baseline characteristics and survival of TAVI patients 
versus medically treated patients.3 
                                                     
3 These comparisons should only be assessed in conjunction with the described baseline differences 
between the respective patient groups. 
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3 Results  
3.1 Systematic review on TAVI 
3.1.1 Results of literature search 
As illustrated in Figure 2, the original literature searches identified a total of 1,849 citations of 
which 1,590 citations were excluded based on a systematic screening of titles and abstracts (mostly 
laboratory and animal studies, case reports, editorials, commentaries, and non-English and non-
German publications). 259 potentially relevant publications were retrieved for full text screening. 
Based on the full text screening, another 212 publications were excluded. Together with 10 poten-
tially relevant publications identified through supplementary EMBASE and MEDLINE database 
alerts and cross-referencing, 57 reports were selected for data extraction. These reports underwent a 
third screening based on a detailed evaluation of extracted data - leaving 12 4 primary publications 
and 7 systematic reviews/ publications from HTA institutes for inclusion in the information synthe-
sis.5 No distinct health economic evaluation of TAVI was identified through the literature search. 
 
3.1.2 Description and information synthesis of primary publications 
3.1.2.1 Study quality 
The quality of all included primary publications on TAVI was assessed along the criteria of the 
checklist #2a of the GSWG (German Scientific Working Group for Health Care 2000c). Each of the 
12 primary publications included in the information synthesis was evaluated (Appendix 7.7.1). The 
quality assessment below was structured according to the sections of the checklist: patient selec-
tion, assignment and participation, intervention/exposure, study administration, outcome measure-
ment, drop-outs, statistical analysis, and discussion.  
Except for three retrospective studies, the inclusion and exclusion criteria were defined and estab-
lished before the intervention. The diagnostic criteria for symptomatic severe AS were described 
and a reliable and valid assessment of disease status was ensured by echocardiographic and Dop-
pler hemodynamic assessment. All included patients met the current eligibility criteria defined for 
                                                     
4 Results from the two largest industry-sponsored US and European registries (SOURCE and 
PARTNER EU) could not be considered because full-text publications of results were missing. 
5 The complete lists of relevant primary and secondary publications included in the review on TAVI 
are provided in the bibliography sections 6.2.1 and 6.2.2. 
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TAVI, and could thus be considered as “standard users” of the intervention. The recruitment period 
was specified in all studies whereas the mean follow-up was only provided in seven studies. 
The included studies were neither randomized nor blinded. Seven studies were designed as obser-
vational clinical case series without control groups, and five as small comparative cohort studies. 
For latter, the interventional cohorts and control groups were recruited from a patient population of 
patients referred for TAVI intervention or compared to patients undergoing surgical AVR. The con-
trol cohorts were comparable in respect to demographic and clinical characteristics. 
A comparable and valid assessment of the intervention was generally provided in all studies. Out-
come measurement was usually conducted centrally. In the only multi-center study, a systematic 
workup protocol ensured consistent measurement. Details on co-therapies were not provided. 
In all studies, procedural success, post-procedural mortality and complications were a priori de-
fined as primary endpoints. In addition, echocardiographic and clinical parameters were collected 
which are of particular interest from the patients’ perspective. However, none of the studies as-
sessed the impact on patients’ QoL. Only few case series assessed the distribution of prognostic 
factors. 
Most included studies reported complete follow-up data. The remaining studies provided little or 
no details on the completeness of follow-up.  
Primary and secondary endpoints were reported for all patients undergoing the intervention. For 
control groups, only primary endpoints were reported. Testing methods to compare metric and cat-
egorical variables and p-values of the corresponding hypothesis tests were described. Several stud-
ies provided CI or standard errors to assess the precision of effect estimates. 
All study results were analyzed in the context of previous evidence from other relevant studies, and 
references to the study hypothesis were made. A generalization of the statements on the effective-
ness of TAVI in patient populations was raised in some publications. Most publications commented 
on possible sources of distortion and limitations of the study design, e.g. observational or retrospec-
tive nature, uncertainties in respect to patient selection and the impact of learning curve. In general, 
statistical limitations, e.g. small sample size, were discussed. 
3.1.2.2 Study characteristics 
As a result of the systematic literature search, 12 studies were identified for the information synthe-
sis. The general study characteristics to describe the study design, the TAVI approach and valve 
type for each case series are provided in Table 6. All included studies were conducted in either 
Western European or North American/Canadian specialized tertiary referral centers and reported 
results of observational studies including patients who underwent TAVI via the TV or TA approach. 
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The studies’ patient enrollment period ranged from January 2005 until June 2009, and they were 
published between 2008 and 2010. Except for the Canadian multi-center study by Rodés-Cabau, J. 
et al. 2010, the authors reported results collected in a single center. None of the studies was ran-
domized or blinded, but three publications (Rajani, R. et al. 2010, Kapadia, S. R. et al. 2009, Otten, 
A. M. et al. 2008) conducted small comparative cohort studies to compare TAVI patients to control 
groups of patients referred for TAVI, but undergoing either alternative aortic valve interventions 
(surgical AVR or palliative BAV) or medical therapy. Walther, T. et al. 2010 conducted a propensi-
ty-matched comparison between TAVI and surgical AVR. Zierer, A. et al. 2009 evaluated outcomes 
of two matched groups of patients undergoing either TAVI or minimally invasive surgical AVR. 
Five series had ≥ 75 patients (range 75-339) (Rodés-Cabau, J. et al. 2010, Walther, T. et al. 2010, 
Himbert, D. et al. 2009, Webb, J. G. et al. 2009, Grube, E. et al. 2008), and the remaining seven 
series had <75 patients (range 18-50) (Rajani, R. et al. 2010, Al-Attar, N. et al. 2009, Kapadia, S. R. 
et al. 2009, Thielmann, M. et al. 2009, Ye, J. et al. 2009, Zierer, A. et al. 2009, Otten, A. M. et al. 
2008). The number of patients captured by this review totaled 1,049 of which almost half (48.3% 
(n=507)) stemmed from the two largest studies from Canada (Rodés-Cabau, J. et al. 2010, Webb, J. 
G. et al. 2009). There were three studies exclusively on the TV-TAVI approach with the CoreValve 
device (20.3% (n=213)) (Rajani, R. et al. 2010, Grube, E. et al. 2008, Otten, A. M. et al. 2008). The 
other studies implanted valve prostheses manufactured by Edwards (Cribier Edwards/ Edwards 
Sapien) (79.7% (n=836)). Of these, three series report exclusively on the TA-TAVI approach (14% 
(n=147)) (Walther, T. et al. 2010, Ye, J. et al. 2010, Zierer, A. et al. 2009) and five of patients who 
underwent either approach (TV 35.8% (n=376), TA 28.1% (n=295)). In the study of Kapadia, S. R. 
et al. 2009, the TAVI approach was not specified (1.7% (n=18)). All studies clearly defined the 
techniques of the standard TAVI intervention, and there was reasonable consistency in their de-
scription of the techniques used for each access route. Three studies were based on retrospective 
data reviews (Rajani, R. et al. 2010, Walther, T. et al. 2010, Zierer, A. et al. 2009), the remaining 
nine were prospective studies. The mean clinical follow-up duration was 9.6 months (range 8-13 
months)/ 10.4±6 months. One-year follow-up data was reported by all included studies.  
3.1.2.3 Patient characteristics 
Details on demographic baseline characteristics are provided in Table 7. Most case series re-
quired a minimum patient age of 75 years for enrollment, thus, the mean age of included series was 
consistently high with a mean of 82 years (range 80.1-85 years)/ 81.6±7.4 years. The difference of 
mean age between patients undergoing the TV and TA approach (82.7 years (range 79.6-85 years)/ 
81.6±7.4 years versus 81.6 years (range 80-85 years)/ 81.4±7.6 years) was not significant (p-
value=0.154). Mean 45% (range 23%-67%) of the patients were male, with a significantly higher 
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share of male patients of 51% (range 38%-58%) among those treated via the TV access route ver-
sus 36% (range 23%-67%) in the TA subgroup (p-value<0.0001).  
All included patients presented with pre-procedural outcome measures that indicated severe AS 
according to the 2006 position statement of the American College of Cardiology (ACC)/ American 
Heart Association (AHA) (Bonow, R. O. et al. 2006). The patients were symptomatic, and consid-
ered “inoperable” or at “very high risk” for surgery, however, no consistent definition for these 
terms was applied; five studies referred only to the estimated operative risk score and age (Rodés-
Cabau, J. et al. 2010, Rajani, R. et al. 2010, Walther, T. et al. 2010, Al-Attar, N. et al. 2009, Thiel-
mann, M. et al. 2009). Details on the baseline measures are summarized in Table 7. 
All but one (Rodés-Cabau, J. et al. 2010) included studies calculated the logistic EuroSCORE to 
determine the estimated operative risk which was mean 27.8% (range 15%-44.2%)/ 
27.5%±15.6% for all patients. Due to the patient selection process illustrated by Figure 1, patients 
treated by the TV route generally have a lower risk profile than those treated by the TA approach. 
This different risk profile was reflected in a significant difference of mean logistic EuroSCORE 
results between TV and TA subgroups (23.9% (range 15%-38.1%)/ 23.6%±14.2% versus 34% 
(range 28%-52%)/ 33.7%±15.5%) (p-value<0.0001). Nine studies conducted an operative risk es-
timation via the score of the Society of Thoracic Surgeons (STS) (Rodés-Cabau, J. et al. 2010, Wal-
ther, T. et al. 2010, Al-Attar, N. et al. 2009, Himbert, D. et al. 2009, Kapadia, S. R. et al. 2009, 
Webb, J. G. et al. 2009, Thielmann, M. et al. 2009, Ye, J. et al. 2009, Grube, E. et al. 2008). The 
mean STS score was 11.3% (range 8.9%-17.9%)/ 11.8%±7.4% for all patients and 10.1% (range 
8.7%-15.1%)/ 10.5%±6.7% and 12.9% (range 10.3%-19.9%)/ 13.3%±8.2% for TV and TA sub-
groups, respectively (p-value<0.0001).  
The clinical status of TAVI patients was usually assessed by means of the NYHA functional classi-
fication scale which represents a measure to assess the functional impact of the valvular dysfunc-
tion. NYHA classification ranges from class I in which the patient has no limitation in daily physi-
cal activity, to class IV, in which the patient is breathless at rest. Except for two studies (Rodés-
Cabau, J. et al. 2010, Otten, A. M. et al. 2008), all included studies reported the mean NYHA func-
tional class at baseline which was mean 3.2 (range 2.6-3.7)/ 3.3±0.6.6 Eight studies (n=490) pro-
vided the distribution of patients per NYHA class at baseline (Rajani, R. et al. 2010, Walther, T. et 
al. 2010, Al-Attar, N. et al. 2009, Himbert, D. et al. 2009, Kapadia, S. R. et al. 2009, Thielmann, M. 
                                                     
6 It is recognized that NYHA classes are discrete variables, and therefore, the calculation of a mean 
might distort the evidence. However, two studies considered in this review only provided a mean 
NYHA class, and would not have been considered otherwise. 
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et al. 2009, Webb, J. G. et al. 2009, Ye, J. et al. 2009): 1% (n=5), 8.6% (n=42), 60.8% (n=298), and 
29.6% (n=145) were in NYHA class I, II, III, and IV, respectively. 
3.1.2.4 Primary outcome measures (safety) 
Mean overall procedural success rate, defined by most authors as implantation of a functioning 
prosthetic valve in the correct position and without intra-procedural mortality, was 93.3% (n=948; 
range 86%-100%) for all included TAVI interventions. Success rates extracted from each included 
study are provided in Table 8. Due to the high technical demand of the TV access route, the mean 
procedural success rate of 89.6% (n=382; range 85.7%-100%) in these procedures was significantly 
lower as compared to the TA access route with a mean success rate of 97.3% (n=353; range 96.1%-
100%) (p-value=0.0002). In TV series, the mean procedural success rate ranged from 85.7% in an 
older series of 136 patients published in 2008 (Grube, E. et al. 2008) to 100% in a recently pub-
lished, smaller series of 39 patients at very high surgical risk (Thielmann, M. et al. 2009). For TA 
series, four smaller series including in total 47 patients reported 100% success rates (Al-Attar, N. et 
al. 2009, Himbert, D. et al. 2009, Zierer, A. et al. 2009, Ye, J. et al. 2009). The success rates of the 
two most recent and largest TA series were 96.1% (Rodés-Cabau, J. et al. 2010) and 97% (Walther, 
T. et al. 2010). One publication (Otten, A. M. et al. 2008) did not report the procedural success rate.  
Only three studies with a total patient population of n=428, provided detailed reasons for technical 
failure of TV procedures (Rodés-Cabau, J. et al. 2010, Al-Attar, N. et al. 2009, Thielmann, M. et al. 
2009). The procedures failed due to the inability to pass the iliac artery in 2.6% (n=11) of patients, 
to cross the native valve with the prosthesis in 1.6% (n=7), prosthesis embolization in 1.4% (n=6), 
major vascular injuries in 0.5% (n=2), cardiac perforation 0.5% (n=2), or procedural death in 1.4% 
(n=6). For TA procedures, only one study (Walther, T. et al. 2010) (n=100) reported the following 
reasons for technical failure: dissection of aortic root in 1% (n=1) of patients, valve dislocation in 
1% (n=1), and left main stem occlusion in 1% (n=1). Survivors of failed TAVI procedures were 
either converted to surgical AVR including full sternotomy (Walther, T. et al. 2010) or treated med-
ically (Al-Attar, N. et al. 2009). 
Except for two studies (Zierer, A. et al. 2009, Otten, A. M. et al. 2008), all included studies reported 
major procedural and post-procedural complications7 (n=989; thereof TV n=550/ TA n=421). 
As illustrated in Table 9, the mean incidence of the adverse events in total and per subgroup was 
the following: major vascular complication 3.1% (n=31; range 0%-12.8%), for TV 4.5% (n=25; 
range 0%-33.3%), and for TA 2.4% (n=6; range 0%-13.3%) (p-value=0.0061); cerebrovascular 
                                                     
7 If a publication reported any adverse events, it was assumed that if a type of major complication 
was not mentioned, it would not have occurred. 
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accident/ stroke 2.9% (n=29; range 0%-4.2%), for TV 4.4% (n=24; range 0%-4.4%), and for TA 
1.2% (n=5; range 0%-6.7%) (p-value=0.004); myocardial infarction (MI) 0.8% (n=8; range 0%-
3.8%), for TV 0.7% (n=4; range 0%-2.2%), and for TA 1% (n=4; range 0%-3.8%) (p-value=0.703); 
cardiac tamponade 1.4% (n=14; range 0%-6%), for TV 1.5% (n=8; range 0%-6.7%), and for TA 
1.4% (n=6; range 0%-13.3%) (p-value=0.97); atrioventricular heart block requiring permanent 
pacemaker (PPM) insertion 9.7% (n=96; range 0%-6%), for TV 12% (n=66; range 5%-34.2%), and 
for TA 6.9% (n=29; range 0%-11.5%) (p-value=0.008); “valve in valve” 1.8% (n=18; range 0%-
4%), for TV 1.6% (n=9; range 0%-2.9%), and for TA 2.1% (n=9; range 0%-8.3%) (p-value=0.566). 
Other less frequently observed complications included renal failure (Rajani, R. et al. 2010, Webb, J. 
G. et al. 2009), major access site complication/ infection (Rodés-Cabau, J. et al. 2010, Kapadia, S. 
R. et al. 2009, Webb, J. G. et al. 2009), major bleeding (Ye, J. et al. 2009, Kapadia, S. R. et al. 
2009), prolonged ventilation (Kapadia, S. R. et al. 2009, Ye, J. et al. 2009, Webb, J. G. et al. 2009), 
and valve embolization (Thielmann, M. et al. 2009). 
The mean combined procedural, post-procedural and cumulative inhospital/30-day mortality was 
11.4% (n=116; range 5.3%-23%) (95%-CI: 9.4%-13.3%) as reported by all but one (Otten, A. M. et 
al. 2008) included studies. For TV procedures, the mean inhospital/30-day mortality was 9.5% 
(n=53; range 5.3%-13.3%) (95%-CI: 7.1%-12%), which was significantly lower than for TA proce-
dures with a mean of 14% (n=62; range 10%-27%) (95%-CI: 10.8%-17.2%) (p-value=0.03). De-
tailed 30-day mortality rates from each included study are provided in Table 8. In addition, Figure 3 
visualizes the 30-day mortality rates differentiated by the chosen interventional access route.  
The mean 1-year survival rate after TAVI derived from all included studies was 75.9% (range 
64.1%-87%)/ 74.4%±6.2% (95%-CI: 73.3%-78.4%), with significant difference between TV and 
TA subgroups (79.2% (range 68.1%-87%)/ 76.1%±6.5% (95%-CI: 75.5%-82.8%) versus 73.6% 
(range 60%-78%)/ 74.9%±6.7% (95%-CI: 69.2%-77.9%)) (p-value=0.041) (Table 8, Figure 4). 
Three authors reported that the incidence of late mortality was mostly non-cardiac and due to 
comorbidities (Rodés-Cabau, J. et al. 2010, Webb, J. G. et al. 2009, Grube, E. et al. 2008). 
None of the studies observed any evidence on structural valve deterioration or other prosthetic 
valve dysfunction during follow-up. 
3.1.2.5 Secondary outcome measures (efficacy) 
The efficacy of TAVI seemed to be good with significant post-TAVI effects. Patients in whom a 
TAVI had been successfully performed were reported to experience an improved valvular function 
and a trend towards an improved ventricular function, in accordance with an improvement in their 
NHYA functional class. The results from included studies were statistically significant and reported 
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efficacy outcomes were consistent. Table 10 provides an overview of the evidence on TAVI effica-
cy. 
3.1.2.5.1 Echocardiographic assessment 
A summary of the reported echocardiographic and clinical baseline measures and post-TAVI out-
comes at 30-day and 1-year follow-up is provided in Table 11. Irrespective of the TAVI approach, 
the mean calculated aortic valve area (AVA) improved significantly after the procedure. Based on 
the observation of a subset of studies which reported data for both 30-day and 1-year follow-up 
(Himbert, D. et al. 2009, Thielmann, M. et al. 2009, Webb, J. G. et al. 2009), the AVA increased by 
over 170% from the pre-procedural baseline of mean 0.61cm² (range 0.6-0.64cm²)/ 0.61±0.19cm² 
for all patients, and 0.61cm² (range 0.6-0.63cm²)/ 0.63±0.16cm² for TV and 0.62cm² (range 0.6-
0.65cm²)/ 0.65±0.17cm² for TA subgroups (p-value=0.374), to mean 1.65cm² (range 1.6-1.73cm²)/ 
1.65±0.44cm² at 30-day follow-up for all patients. Beyond 30-day follow-up, the AVA decreased 
somewhat towards a mean of 1.49cm² (range 1.45-1.7cm²)/ 1.54±0.34cm² observed at 1-year fol-
low-up (Figure 5). 
The assessment of the post-TAVI effect on the transaortic mean gradient was also based on the 
subset of three studies (Himbert, D. et al. 2009, Thielmann, M. et al. 2009, Webb, J. G. et al. 2009). 
At baseline, the mean gradient was 47.6±12.2mmHg8 (range 45.5–52mmHg) for all patients. Im-
mediately after the TAVI intervention and regardless the chosen approach, the mean gradient was 
reported to fall significantly, and to remain stable until 30-day follow-up at a mean of 
10.3±4.2mmHg (range 10-12mmHg). In patients surviving until 1-year follow-up, the mean gradi-
ent remained stable with minor further improvement towards a mean of 10.1mmHg (range 8–
11.2mmHg)/ 10.9±4.9mmHg (Figure 5). 
Four case series reported the pre-procedural baseline and the effect of TAVI on the ventricular func-
tion at 30-day and 1-year follow-up (Walther, T. et al. 2010, Himbert, D. et al. 2009, Thielmann, M. 
et al. 2009, Ye, J. et al. 2009). The pre-procedural left ventricular ejection fraction (LVEF) at 
baseline was mean 53.1%±15.3% (range 46%–56%) for all patients, with no significant difference 
between TV and TA subgroups (52.7%±16% versus 54.2%±14.3%) (p-value=0.164). Post-TAVI, 
the LVEF continued to increase from a mean 56.2% (range 51.1%–59%)/ 55.3%±13.5% at 30-day 
follow-up towards a mean of 60.2% (range 58%–63%)/ 59%±11.4% at 1-year follow-up. 
Aortic regurgitation (AR) was present after TAVI in most patients to some degree as reported by 
seven studies (n=678) (Rodés-Cabau, J. et al. 2010, Al-Attar, N. et al. 2009, Himbert, D. et al. 
2009, Thielmann, M. et al. 2009, Webb, J. G. et al. 2009, Ye, J. et al. 2009, Grube, E. et al. 2008). 
                                                     
8 Mean±SD was reported by all studies. 
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Postoperatively, 80.5% (n=564) of survivors had none to mild (grade 0/I) AR and 16.7% (n=113) 
had moderate (grade II) AR. Severe (grade III) AR occurred in 2.8% (n=19) of patients. Four stud-
ies monitored AR during follow-up and consistently reported that the postoperative degree of AR 
remained unchanged until 1-year follow-up (Walther, T. et al. 2010, Thielmann, M. et al. 2009, 
Webb, J. G. et al. 2009, Ye, J. et al. 2010). 
3.1.2.5.2 Functional improvement 
Eight studies reported the distribution of patients per NYHA class at baseline (Rajani, R. et al. 
2010, Walther, T. et al. 2010, Al-Attar, N. et al. 2009, Himbert, D. et al. 2009, Kapadia, S. R. et al. 
2009, Thielmann, M. et al. 2009, Webb, J. G. et al. 2009, Ye, J. et al. 2009): 1% (n=5), 8.6% 
(n=42), 60.8% (n=298), and 29.6% (n=145) were in NYHA class I, II, III, and IV respectively. The 
mean NYHA class was 3.2 (range 2.6-3.7)/ 3.3 ±0.6 without significant difference between TV (3.3 
(range 2.6-3.5)/ 3.3±0.7) and TA (3.2 (range 2.8-3.4)/ 3.3±0.4) subgroups9 (p-value=0.271) and was 
calculated including two studies without detailed assessment per NYHA class (Grube, E. et al. 
2008, Zierer, A. et al. 2009). 
Three studies provided the pre-procedural NYHA class and the post-TAVI effect at 30-day and 1-
year follow-up in detail per functional classification (Figure 6) (Walther, T. et al. 2010, Thielmann, 
M. et al. 2009, Ye, J. et al. 2009). At 30-day follow-up, 22% (n=31), 51% (n=71), and 26% (n=36) 
of survivors were in classes I, II, and III. At 1-year follow-up, the improvement of functional status 
was sustained with 26% (n=26) of patients in class I, 40% (n=39) in class II, and 34% (n=34) in 
class III. None of the survivors remained in functional class IV at any follow-up interval. The cor-
responding mean NYHA class including one additional study (Grube, E. et al. 2008) was 1.9±0.3 
(range 1.6–2.3) at 30-day and 1.8 ±0.4 (range 1.3–2.4) at 1-year follow-up. 
In addition, two authors described a reduction of at least one functional class in most patients – in 
particular, patients were more likely to be in class I/II compared to III/IV which is the poorest pre-
operative functional status (Webb, J. G. et al. 2009, Al-Attar, N. et al. 2009). 
3.1.2.5.3 Length of hospital stay 
Seven studies reported a mean length of hospital and intensive care unit (ICU) stay associated with 
TAVI: mean stay in hospital was 9.5 days (range 5–19 days), and thereof, mean stay of 2.7 days in 
ICU. Hospital stay for TV patients was not significantly shorter than for TA patients (9 days (range 
5–15 days) versus 10.6 days (range 7–19 days)) (p-value=0.658) (Al-Attar, N. et al. 2009, Himbert, 
                                                     
9 Only partially reported per TA/ TV subgroup. 
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D. et al. 2009, Kapadia, S. R. et al. 2009, Webb, J. G. et al. 2009, Thielmann, M. et al. 2009, Ye, J. 
et al. 2009, Zierer, A. et al. 2009). 
3.1.2.5.4 Quality of life and cost-effectiveness 
None of the included primary publications10 provided data on patients’ QoL before or after TAVI 
procedures or an economic analysis to assess the cost-effectiveness of TAVI. Apart from the length 
of hospital stay11, which is summarized in chapter 3.1.2.5.3, major health cost drivers were not 
reported. 
 
3.1.3 Description and information synthesis of secondary publications 
3.1.3.1 Study quality 
The quality of all included secondary publications was assessed along the criteria of the checklist 
#1b for systematic reviews/ meta-analyses published by the GSWG. Each of the seven secondary 
publications included in the information synthesis was evaluated, and the results are provided in the 
Appendix 7.7.3. In addition, one so-called “rapid HTA” (van Brabandt, H. and Neyt, M. 2008) was 
also assessed along the criteria of the GSWG checklist #1a for context documents (German Scien-
tific Working Group for Health Care 2000a). The quality assessment below was structured accord-
ing to the sections of the checklists: research question, information retrieval and evaluation, infor-
mation synthesis, conclusions, and transferability of results. 
All included systematic reviews aimed to assess the safety and efficacy of TAVI interventions. De-
tails of the literature search (sources, search strategy, and inclusion and exclusion criteria) were 
always documented. Whether the evaluation and extraction of information was conducted by sever-
al independent reviewers remained unclear in most publications. The data extraction was usually 
structured along study and patient characteristics, and key safety and efficacy outcome measures. 
All information syntheses were of qualitative nature, and only three publications evaluated the ex-
                                                     
10 In the course of literature selection, three studies without 1-year follow-up were excluded from 
the information synthesis (Bleiziffer, S. et al. 2009, Ussia, G. P. et al. 2009, Svensson, L. G. 2008). 
These studies reported significant improvement of pre-procedural physical and mental QoL scores 
from pre- to postoperatively at 6 months. Results on QoL improvements beyond 6-months follow-
up have not been published yet. 
11 In Germany, from the statutory payers’ perspective, charges from hospitals are based on diagno-
sis-related groups (DRG) which are independent from the actual length of hospital stay. However, 
DRGs reflect only charges, not actual costs imposed on the public health system. 
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isting evidence systematically. In the conclusions, methodological limitations of the existing evi-
dence were critically discussed by all publications. Specific recommendations, e.g. to health care 
providers or clinicians, were provided in three publications. The remaining four publications post-
poned specific recommendations due to lack of convincing evidence. 
3.1.3.2 Reconciliation of included studies from this work with those included in earlier re-
views 
The literature search for secondary publications on TAVI revealed two systematic reviews pub-
lished in peer-reviewed journals (Yan, T. D. et al. 2010, van Brabandt, H. and Neyt, M. 2008), four 
systematic reviews issued by health technology institutes (Wild, C. and Geiger-Gritsch, S. 2009, 
National Institute for Health and Clinical Excellence (NICE) 2008, Blanchard, S. 2008, Wild, C. et 
al. 2008), as well as one “rapid” HTA (van Brabandt, H. and Neyt, M. 2008) which already provid-
ed a summary of results from the three reviews published earlier in 2008.  
As illustrated in Table 12, the update (Wild, C. and Geiger-Gritsch, S. 2009) of the systematic re-
view of the Austrian Ludwig-Boltzmann-Institut (LBI) from 2008 (Wild, C. et al. 2008) and the 
recent Australian systematic review (Yan, T. D. et al. 2010) concur by two and one publications 
respectively with the references selected for this review. The other secondary publications pub-
lished in 2008 (van Brabandt, H. and Neyt, M. 2008, National Institute for Health and Clinical 
Excellence (NICE) 2008, Blanchard, S. 2008)) and recent published systematic review published in 
2009 by the same authors as the HTA of the Belgian Health Care Knowledge Center (KCE) (van 
Brabandt, H. and Neyt, M. 2009), did not consider the primary publications included for discussion 
in this work. However, earlier publications from the same teams and study centers as the publica-
tions this work was based upon were incorporated in these previous secondary publications. Thus, 
the reviews might bear potential for overlapping patient populations. The overview in Table 12 
compares this work’s references and according related previous publications12 with those of earlier 
systematic reviews/ HTAs to point out potential overlaps with earlier reviews. 
3.1.3.3 Information synthesis 
The following brief descriptions of systematic reviews/ HTAs included in the information synthesis 
of this work summarize the institutional background, objectives, methods, results, and conclusions 
of the authors. 
 
                                                     
12 Related publications were defined as duplicate publications from the same centers with overlap-
ping enrollment period and accumulating number of patients, or increased length of follow-up. 
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Systematic reviews published in peer-reviewed journals 
Yan, T. D. et al. 2010, Australia 
Objectives 
The systematic review assessed the safety and clinical effectiveness of TAVI for patients at high 
surgical risk with severe AS. 
Methods 
Electronic searches were performed in MEDLINE, EMBASE, PubMed, Cochrane Central Register 
of Controlled Trials, CDSR, and Database of Abstracts of Review of Effectiveness from January 
2000 to March 2009. The end points included feasibility, safety, efficacy, and durability. Literature 
selection was conducted by two reviewers. Clinical effectiveness was synthesized through a narra-
tive review with full tabulation of results of all included studies. 
Results 
The review captured the results of 1173 patients from 17 short-term observational studies. The 
safety assessment included overall procedural success rates in a range from 74%-100% and the 
following ranges of 30-day major adverse events: mortality (0%–25%), major ventricular tach-
yarrhythmia (0%–4%), myocardial infarction (0%–15%), cardiac tamponade (2%–10%), stroke 
(0%–10%), conversion to surgery (0%–8%), conversion to valvuloplasty (0%–4%), vascular com-
plication (8%–17%), moderate to major paravalvular leak (4%–35%), “valve-in-valve” (2%–12%), 
and aortic dissection/rupture (0%–4%). With regard to the efficacy of TAVI, the mean AVA im-
proved from a preoperative range from 0.5-0.8 cm² to a range from 1.3–2 cm² after TAVI. The 
mean pressure gradient ranged from 34–54 mmHg before TAVI and from 3–12 mmHg after the 
procedure. The mean length of hospital stay ranged from 7-17 days. Postoperative 6-months mor-
tality ranged from 18%-48%. QoL data retrieved from one study incorporating 40 patients indicat-
ed improvement from preoperatively until 6-months postoperatively (Svensson, L. G. et al. 2008).  
Conclusions 
In their discussion, the authors stressed the potential for serious complications, lacking evidence of 
long-term outcomes including QoL, and inappropriate operative risk estimation methods. There-
fore, the authors recommend that TAVI procedures should be considered only within the boundaries 
of clinical trials and at highly specialized centers with appropriate experience and infrastructure. 
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van Brabandt, H. and Neyt, M. 2009, Belgium 
Institutional background 
This systematic review published in September 2009 was conducted by employees of the Belgian 
KCE (van Brabandt, H. and Neyt, M. 2009).13 
Objectives 
The systematic review aimed at assessing the safety of TAVI and to compare it with published pri-
mary data reporting the risk of surgical AVR in high-risk patients with severe, symptomatic aortic 
AS.  
Methods 
Relevant published and presented primary studies were identified from a search in major databases 
(MEDLINE, EMBASE, CDSR, and CRD), dedicated websites, and through contacts with manu-
facturers which was conducted on December 15, 2008. Structured data extraction included patient 
characteristics, procedural success rate, operative risk status, early and late all-cause mortality. To 
minimize the impact of learning curve and device improvements, only series starting recruitment in 
April 2007 or later (n=1975) were included in the safety assessment. 
Results 
Due to the limited publication period, all peer-reviewed publications were excluded, leaving only 
three industry-sponsored series presented at international meetings for information synthesis: 1. 
“PARTNER EU” (Edwards Sapien) with 130 patients (TV=60/ TA=70); 2. “SOURCE” (Edwards 
Sapien) including 602 patients (TV=293/ TA=309); and 3. “CoreValve 18F EE” with 1,243 patients 
undergoing TV-TAVI. The procedural success rate was high with 97.7%-98.2% in TV and 91% in 
TA series. 30-day mortality rates ranged from 6.4%-7.4% for the TV and 11.6%-18.6% for the TA 
access route. The 6-months mortality rates were reported to range from 10%-25% in TV and 
26.1%-42.8% in TA series. None of the included series starting recruitment after April 2007 report-
ed long-term outcomes, but – inconsistent with inclusion criteria – 1-year survival from previous 
much smaller presented series were reported which ranged between 65%-80% in TV and from 
54.7%-66% in TA series. Secondary outcomes on the efficacy of TAVI were not assessed.  
 
                                                     
13 The same authors wrote the rapid HTA published by the KCE in 2008 (van Brabandt, H. and 
Neyt, M. 2008). 
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Conclusions 
The authors concluded that TAVI procedures, especially via the TA access route, are risky in re-
spect to safety and short-term survival, and thus, should not be performed in clinical routine as long 
as results from a randomized trial become available. 
 
Systematic reviews/ HTAs published by HTA institutes 
Wild, C. and Geiger-Gritsch, S. 2009, LBI Austria 
Institutional background 
The Austrian LBI published this systematic review in 2009 as the first update of its previously pub-
lished systematic review on TV-TAVI (Wild, C. et al. 2008). 
Objectives 
This review aimed to bring the preceding publication (Wild, C. et al. 2008) up to date and to revise 
the resulting recommendation in respect to the safety and efficacy assessment of TAVI compared to 
conservative treatment of patients with severe AS. 
Methods 
The literature search was conducted in 7 major databases (MEDLINE, EMBASE, Cochrane Cen-
tral Register of Controlled Trial, CDSR, Cochrane Database of Review of Effects, CRD database, 
and INAHTA database) and limited to German and English language, and publication date between 
2008 and 2009. Handsearching and industry contacts complemented the electronic search. 
Results 
Compared to the previous review, four additional clinical studies published between 2008 and 2009 
were included which captured the results from 833 TAVI interventions. The outcome parameter of 
these four studies largely complied with the results of the preceding publication, and ranged be-
tween 70%-97% for the procedural success rate, and 8%-40% for 30-day mortality. Further out-
comes were only partially reported. The authors questioned the independence of two industry-
sponsored studies (Piazza, N. et al. 2008, Grube, E. et al. 2008) and therefore, focused their review 
on only two small series (Otten, A. M. et al. 2008, Descoutures, F. et al. 2008). The two studies 
illustrated that a high share of the very old and sick patient population - especially those with a high 
EuroSCORE (>25%) – was prone to refuse the treatment. In one study (Otten, A. M. et al. 2008), in 
100 patients assigned to TAVI, only 39% (n=39) TAVI procedures were performed. Descoutures, F. 
et al. 2008 reported similar observations: of 39 inoperable patients assigned to TAVI, only 31% 
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(n=12) underwent the intervention. The majority of 69% (27) were referred to either medical thera-
py 41% (16), BAV 18% (7), or redirected to surgical AVR 10% (4). On average, the included pa-
tients in NYHA classes III and IV improved their functional status by one class to class III and II, 
respectively. 
Conclusions 
The authors retained their recommendation provided in their previous publication insofar as current 
evidence was low and did not allow a reliable assessment of the safety and the clinical efficacy of 
the TAVI technology. 
 
van Brabandt, H. and Neyt, M. 2008, KCE Belgium 
Institutional background 
This so-called “rapid HTA” was published by the Belgian KCE health technology institute. The 
KCE is in charge of conducting studies that support the political decision making on health care 
and health insurance in Belgium. 
Objectives 
The rapid HTA report summarized current evidence supporting the use of TAVI heart valves in 
degenerative aortic valve disease. 
Methods 
All searches were performed in June 2008. For primary publications and systematic reviews, 
MEDLINE, EMBASE, CRD and Cochrane databases were searched. In addition, a search in CRD 
HTA and INAHTA databases was conducted to identify published HTA reports. Data presented at 
meetings was not included. Data extraction was conducted for all included publications. The search 
on economic evaluations was performed in CRD, CDSR, MEDLINE, and EMBASE databases. 
The search was complemented by handsearching websites of HTA institutes, and reference lists of 
selected studies. Only full economic evaluations, i.e. studies comparing alternative treatments in 
terms of costs and outcomes were eligible for inclusion. The literature search and selection process 
was replicated by a second reviewer.  
Results 
Observational data from series published in peer-reviewed journals and data presented at interna-
tional cardiology conferences were included. Procedural success rates of 68%-93% in published 
series, and up to 100% in unpublished data, indicated that TAVI procedures are feasible in the 
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hands of experienced teams. However, TAVI was associated with a high risk: 30-day mortality rates 
ranged from 6.4%-13.2% in TV, and 8%-22.5% in TA patients. Vascular complications occurred – 
especially when the TV access route was chose – in 10%-15% of patients. Stroke was also ob-
served more frequently in TV patients, and was reported in 3%-10% of cases. Efficacy of TAVI was 
reported to be good: improvement of NYHA functional class, and improved valvular function were 
observed in the majority of included patients. Reported 6-months survival rates were based on un-
published data, and mortality ranged from 10%-21.7% in TV and 26.1%-45% in TA series. Long-
term data (≥ 1-year follow-up), and data on QoL were not reported. None of the included HTA re-
ports provided a full economic analysis. A market price of TAVI devices of 2000€ and an annual 
number of eligible Belgian patients of 135-290 were estimated. 
Conclusions 
A reimbursement was not recommended because of patient safety concerns, and a poorly defined 
target population. If RCT data provided evidence on clinical safety and efficacy, the supplemental 
cost-effectiveness and budget impact analyses deferred in this report would need to be conducted. 
Until then, an uncontrolled diffusion of the TAVI technique patients should only be subjected to 
TAVI within the boundaries of an RCT. 
 
Summary of earlier systematic reviews/ HTAs captured in the review of the Belgian KCE 
HTA 
In addition to the “rapid HTA” of the Belgian KCE (van Brabandt, H. and Neyt, M. 2008), three 
further systematic reviews/ HTAs on TAVI have been published in 2008 by health technology insti-
tutes from UK, France and Austria (National Institute for Health and Clinical Excellence (NICE) 
2008, Blanchard, S. 2008, Wild, C. et al. 2008). As illustrated in Table 13, the case series included 
for information synthesis in these reviews are highly consistent with those from the rapid HTA of 
the Belgian KCE. Latter provides an extensive overview of methods, outcomes, and ensuing guid-
ance of the NICE, HAS, and LBI systematic reviews. Therefore, this work only summarized the 
key results in Table 14 and resulting recommendations for each of these earlier reviews below in 
the text. 
In summary, all systematic reviews/ HTAs published in 2008 which were captured in the work of 
van Brabandt, H. and Neyt, M. 2008 concluded from observational series of high-risk elderly pa-
tients that short-term efficacy of TAVI procedures was promising. However, limitations of pub-
lished series, such as small patient populations, missing long-term follow-up or QoL effects, im-
peded reliable full-scale HTA reports, including economic evaluations. All authors emphasized the 
requirement for re-assessments as soon as evidence from the PARTNER U.S. RCT (Placement of 
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AoRTic traNscathetER Valve trial in the U.S. [PARTNER U.S.]; ClinicalTrials.gov identifier 
NCT00530894) would be available. In the light of the first published results from the PARTNER 
U.S. RCT in September 2010 (Leon, M. B. et al. 2010), the recommendations summarized below 
will now require a re-assessment and can thus, only be regarded as provisional. 
 
National Institute for Health and Clinical Excellence (NICE) 2008, NICE UK  
The “Interventional procedure overview of transcatheter aortic valve implantation for aortic steno-
sis” published by the NICE was based on a rapid literature review and specialist opinion and, ex-
plicitly, should not be regarded as a definitive HTA of the procedure. The authors remarked that 
current evidence on TAVI for AS was limited to small numbers of patients who were considered to 
be at high risk for conventional surgery. It showed good short-term efficacy, but there was little 
evidence on long-term outcomes. There was a potential for serious complications, but the patients 
on whom this procedure had been used had a poor prognosis without treatment and were at high 
risk if treated by open heart surgery. The authors encouraged clinicians to ensure that patients un-
derstand the uncertainties about the procedure. They recommended that TAVI should be performed 
only by clinicians and interventional cardiology teams with special training. Units undertaking this 
procedure should have both cardiac and vascular surgical support for emergency treatment of com-
plications. Details about all patients undergoing TAVI should be entered into a central database. 
 
Blanchard, S. 2008, HAS France 
The French review recommended a conditional reimbursement of TAVI for patients that are con-
sidered at high risk of conventional surgery or deemed inoperable. They estimated that without an 
expansion of the indication, in minimum 600 patients per year in France would be eligible for 
TAVI. The following prerequisites were formulated: reimbursement limited in time and limited to 
specialized cardiac centers, and all patients to be included in a mandatory registry. A re-assessment 
of reimbursement is intended when more data on clinical effectiveness will become available. 
 
Wild, C. et al. 2008, LBI Austria 
This systematic review concluded that current evidence from small patient series with short follow-
up is low and would not allow a reliable assessment of the safety and the clinical effectiveness of 
TAVI. The number of annual eligible patients in Upper Austria, and the costs for a TAVI interven-
tion were estimated in a range of 30 patients and 2400€ per intervention, respectively. The authors 
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objected the reimbursement of TAVI procedures, and recommended to use TAVI only as a palliative 
procedure until reliable clinical data is available. 
 
3.2 Systematic review on medical therapy of AS 
3.2.1 Results of literature search 
As illustrated in Figure 7, the original literature search identified 189 citations of which 169 cita-
tions were excluded based on a systematic screening of titles and abstracts (mostly editorials, 
commentaries, and non-English and non-German publications). Together with 11 potentially rele-
vant publications identified through supplementary EMBASE and MEDLINE database alerts, and 
handsearching the reference lists of key papers, 31 reports underwent a detailed full-text screening 
- leaving 11 reports to be included in the literature synthesis 14, 15. 
 
3.2.2 Description and information synthesis 
3.2.2.1 Study quality 
The quality of all included primary publications was assessed along the criteria of the checklist #2a 
of the GSWG. Each of the 11 primary publications included in the information synthesis was evalu-
ated. The evaluation results for each publication are provided in the Appendix 7.7.2. The quality 
assessment below was structured according to the sections of the checklist: patient selection, as-
signment and participation, intervention/exposure, study administration, outcome measurement, 
drop-outs, statistical analysis, and discussion.  
Due to the retrospective nature of most included studies, the inclusion and exclusion criteria could 
not be defined and established before the intervention. The diagnostic criteria for symptomatic 
severe AS were described and a reliable and valid assessment of disease status was ensured by 
echocardiographic and Doppler hemodynamic assessment extracted from clinical records. The re-
cruitment period and mean follow-up were provided in most studies. 
                                                     
14 Three comparative cohort studies were also included for the review on TAVI (chapter 3.1.1) (Ra-
jani, R. et al. 2010, Kapadia, S. R. et al. 2009, Otten, A. M. et al. 2008). 
15 The complete list of relevant publications included in the review on medical therapy is provided 
in the bibliography section 6.2.3. 
 37 
None of the studies was randomized or blinded, but most attempted to match exposed patients to 
control groups with comparable demographic and clinical characteristics. A comparable and valid 
assessment of the intervention of the treatment cohorts was generally provided in all studies. De-
tails on co-therapies of control groups were not provided. In all studies, outcome measurement was 
usually conducted centrally and based on retrospective reviews of clinical records. Little or no de-
tails on the completeness of follow-up were provided. All studies reported primary and secondary 
endpoints. Testing methods to compare metric and categorical variables between groups and p-
values of the corresponding hypothesis tests were described. Several studies provided CI or stand-
ard errors to assess the precision of effect estimates. 
The study results were analyzed in the context of previous evidence, and they usually addressed the 
study hypothesis. Most publications commented on the methodological limitations of the non-
randomized study design and the external validity of their results. Discussion of statistical uncer-
tainties was mostly missing. 
3.2.2.2 Study characteristics 
For the following information synthesis, 11 relevant primary publications on medical therapy of AS 
were identified (bibliography section 6.2.3). The key characteristics of each study are summarized 
in Table 15. All included publications were observational comparative cohort studies with control 
groups of medically treated patients that did not receive an intervention – either they refused or 
were not offered aortic valve implantation. The treatment groups of the studies consisted of patients 
that underwent either TAVI (Rajani, R. et al. 2010, Kapadia, S. R. et al. 2009, Otten, A. M. et al. 
2008), surgical AVR (Bakaeen, F. G. et al. 2010, Kapadia, S. R. et al. 2009, Bach, D. S. et al. 2009, 
van Geldorp, M. W. A. et al. 2009, Kojodjojo, P. et al. 2008, Otten, A. M. et al. 2008, Charlson, E. 
et al. 2006, Varadarajan, P. et al. 2006b, Iung, B. et al. 2005), or palliative BAV (Kapadia, S. R. et 
al. 2009, O'Keefe, J. H., JR et al. 1987, Otten, A. M. et al. 2008). Eight studies were based on 
retrospective data reviews (Bakaeen, F. G. et al. 2010, Rajani, R. et al. 2010, Bach, D. S. et al. 
2009, van Geldorp, M. W. A. et al. 2009, Kojodjojo, P. et al. 2008, Charlson, E. et al. 2006, 
Varadarajan, P. et al. 2006b, O'Keefe, J. H., JR et al. 1987) and three collected data prospectively 
(Kapadia, S. R. et al. 2009, Otten, A. M. et al. 2008, Iung, B. et al. 2005). The studies’ data collec-
tion periods ranged from January 1978 until June 2009, and, except for one (O'Keefe, J. H., JR et 
al. 1987), they were published between 2005 and 2010. The studies were conducted in centers from 
Western Europe (UK: Rajani, R. et al. 2010, Kojodjojo, P. et al. 2008, Netherlands: Kapadia, S. R. 
et al. 2009, Otten, A. M. et al. 2008, and France: Iung, B. et al. 2005), and North American centers 
(Bakaeen, F. G. et al. 2010, Bach, D. S. et al. 2009, Kapadia, S. R. et al. 2009, Charlson, E. et al. 
2006, Varadarajan, P. et al. 2006b, O'Keefe, J. H., JR et al. 1987). Three studies included < 50 pa-
tients (range 16-47) (Rajani, R. et al. 2010, Kapadia, S. R. et al. 2009, Otten, A. M. et al. 2008), and 
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eight studies >50 patients (range 50-277) (Bakaeen, F. G. et al. 2010, Bach, D. S. et al. 2009, van 
Geldorp, M. W. A. et al. 2009, Kojodjojo, P. et al. 2008, Charlson, E. et al. 2006, Varadarajan, P. et 
al. 2006b, Iung, B. et al. 2005, O'Keefe, J. H., JR et al. 1987). The total number of medically treat-
ed patients captured by this review was n=946.  
In 7 studies (n=797), the control group consisted exclusively of patients treated by surgical AVR 
(Bakaeen, F. G. et al. 2010, Bach, D. S. et al. 2009, van Geldorp, M. W. A. et al. 2009, Kojodjojo, P. 
et al. 2008, Charlson, E. et al. 2006, Varadarajan, P. et al. 2006b, Iung, B. et al. 2005). Two studies 
(n=52) analyzed the treatment assignment for high-risk, elderly patients, and compared the out-
comes in medically treated patients with those of all available interventional treatment forms for 
AS, i.e. TAVI, surgical AVR, and BAV (Kapadia, S. R. et al. 2009, Otten, A. M. et al. 2008). One 
recent study (n=47) investigated the survival benefit of TAVI patients against those managed medi-
cally – either with or without concomitant BAV (Rajani, R. et al. 2010). In one case series, out-
comes of medical therapy for 50 BAV candidates that refused the intervention were described 
(O'Keefe, J. H., JR et al. 1987). In 1987, when this series was published, BAV was the only treat-
ment option for inoperable patients with severe AS that would nowadays be eligible for TAVI. The 
clinical follow-up period was specified in eight studies and was mean 19.6 months (range 6–30 
months)/ 15.5±13.7 months16 (Rajani, R. et al. 2010, Bach, D. S. et al. 2009, Kapadia, S. R. et al. 
2009, van Geldorp, M. W. A. et al. 2009, Kojodjojo, P. et al. 2008, Otten, A. M. et al. 2008, Vara-
darajan, P. et al. 2006b, O'Keefe, J. H., JR et al. 1987). In minimum, the included studies reported 
1-year follow-up data.  
3.2.2.3 Patient characteristics 
Details on pre-procedural demographic, clinical and echocardiographic patient characteristics are 
provided in Table 16. The age of included patients was mean 79.9 years (range 73.3-86.2 years)/ 
79.4±10.1 years (p-value<0.0001).17 On average, 47% (range 29.3%-72%) of the included patients 
were males (p-value=0.385). Where a baseline was provided, the patients consistently presented 
with characteristics of severe AS as assessed by echocardiographic measurement of the degree of 
AS. 
Three studies (Kapadia, S. R. et al. 2009, Rajani, R. et al. 2010, van Geldorp, M. W. A. et al. 2009) 
reported the functional status assessed by NYHA class. The mean NYHA class at baseline was 2.7 
                                                     
16 The difference between means for all included studies compared to studies reporting the SD was 
significant for the follow-up duration (p-value<0.0001). 
17 In this part of the review, levels of significance (p-values) indicate the comparison between med-
ically managed patients and TAVI patients. 
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(range 2.4–3.5). The detailed distribution of patients per class was only provided for 83 patients 
from two studies (Rajani, R. et al. 2010, Kapadia, S. R. et al. 2009): 10% (n=8) of these patients 
were in class I, 17% (n=14) in class II, 51% (n=42) in class III, and 23% (n=19) in class IV (p-
value<0.0001).  
The pre-procedural estimation of operative risk resulted in a mean logistic EuroSCORE of 13.5% 
(range 9%-25.4%)/ 13.6%±11.3% (p-value<0.0001) as reported by six studies (Bakaeen, F. G. et al. 
2010, Rajani, R. et al. 2010, Kapadia, S. R. et al. 2009, van Geldorp, M. W. A. et al. 2009, Ko-
jodjojo, P. et al. 2008, Otten, A. M. et al. 2008). In addition, Kapadia, S. R. et al. 2009 reported a 
mean STS score of 12.6%±9.2% and Bach, D. S. et al. 2009 a median STS score of 3.8% (inter-
quartile range 2.1%–7.3%). 
3.2.2.4 Primary outcome measures (safety) 
None of the included studies reported data on the incidence of complications. The mean 1-year 
survival rate of medically treated patients was 62.4% (range 40%-84.8%)/ 69.8%±10.35% (95%-
CI: 59.3%-65.5%) (p-value<0.0001). As illustrated in Figure 8, the reported survival rates were 
consistent with two exceptions: a survival rate of 40% was reported in a small cohort of 16 high-
risk patients who refused TAVI (Otten, A. M. et al. 2008), and a favorable 84.8% survival rate oc-
curred in a cohort of 72 patients that were denied surgical AVR (Iung, B. et al. 2005). The authors 
of latter argued that the inclusion of non-hospitalized potentially “healthier” patients from outpa-
tient clinics might have accounted for this exceptional outcome. None of the studies provided de-
tails on causes of deaths to assess whether they were caused by cardiac or other causes. 
3.2.2.5 Secondary outcome measures (efficacy) 
None of the included studies provided any follow-up data on secondary outcome measures for 
medically treated patients. 
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4 Discussion 
4.1 Research context 
With the population aging, AS is becoming a more prevalent public health issue. As soon as symp-
toms develop, medical therapy is unlikely to modify the dismal course of the disease. Median sur-
vival after the onset of heart failure, syncope, and angina is 11 months, 27 months, and 45 months, 
respectively (Horstkotte, D. and Loogen, F. 1988). Valve replacement is therefore indicated once 
patients develop symptoms (Bonow, R. O. et al. 2006, Vahanian, A. et al. 2007). Surgical AVR 
remains the therapeutic gold standard, but open heart surgery involves significant risks, in particu-
lar for elderly and frail patients. For this reason, many elderly patients are denied surgery. In the 
past, these patients could only be managed conservatively with medical therapy or palliative BAV. 
With TAVI, an additional, less invasive option has emerged for these “inoperable” patients. Since 
the first TAVI was performed by Cribier, A. et al. in 2002, many thousands of TAVI devices have 
been implanted in high-risk patients worldwide. 
Until the data freeze for this work on April 30, 2010, no randomized trials have compared TAVI 
with conservative medical treatment yet, and the clinical experience with TAVI is deducted mainly 
by short-term results. However, the finalization of this work in September 2010 coincided with the 
publication of the results from the first PARTNER U.S. RCT study which compared TV-TAVI ver-
sus surgical AVR in patients at high surgical risk and TV-TAVI versus medical therapy or BAV in 
patients who are denied surgery due to extreme surgical risk (Leon M. B. et al. 2010). Therefore, 
the RCT data could not be considered as part of the formal information synthesis. Nonetheless, for 
informational purposes, the results reported by Leon and his colleagues are discussed below against 
the background of our findings. 
Few systematic reviews on the safety and efficacy of TAVI procedures have been conducted, but 
none of them have focused on 1-year follow-up data nor have earlier reviews performed a compari-
son with recent evidence on medical therapy. To complement previously published reviews on 
TAVI, the present work followed the formal methodology recommended by the toolkit of the 
GSWG (German Scientific Working Group for Health Care 2000) to address the following objec-
tives: firstly, in view of available observational series, to objectively assess safety and efficacy of 
TAVI up to 1-year follow-up, and secondly, to substantiate 1-year survival benefits after TAVI ver-
sus 1-year survival of medically treated patients with a comparable clinical profile. 
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4.2 Safety of TAVI and comparison with medical therapy of AS 
Concerning the safety of TAVI, the main finding resulting from the two systematic reviews is that 
high-risk, elderly patients undergoing TAVI have a better outcome in terms of absolute 1-year sur-
vival compared with their medically treated counterparts. This finding is important as it provides an 
indication of the potential survival benefit of TAVI of up to +16.8% for a group of patients in 
whom there was previously no effective treatment option. The magnitude of this result corresponds 
well to the 20% survival benefit reported by the PARTNER U.S. trial for TV-TAVI procedures (Le-
on M. B. et al. 2010). Yet it remains unclear, whether patients actually gain prolonged survival, 
taking into account the risk of procedure-related mortality as well as from underlying comorbidi-
ties. As illustrated by Figure 9, the mean 1-year survival rate after TAVI is 75.9% (95%-CI: 73.3%-
78.4%) versus 62.4% (95%-CI: 59.3%-65.5%) with medical therapy. Nonetheless, the lower 
boundary of the CI for the TA subgroup survival rate comes close to the upper boundary of the CI 
of medically treated patients. This can at least partly be explained by a high procedural mortality 
and the very poor general condition of these patients with inherent mortality risk, questioning the 
appropriateness of AS intervention in this population.  
Consistent with previous secondary publications (Yan, T. D. et al. 2010, van Brabandt, H. and Neyt, 
M. 2009), the collated data on short-term safety presented in this review demonstrates that TAVI is 
feasible with procedural success rates ranging from 86%–100% (TV-TAVI 85.7%-100% versus TA-
TAVI 95.8%-100%), yet it remains a high-risk procedure. In recent series included in this review, 
30-day mortality rates, which most likely reflect procedure-related mortality, ranged from 5.3%-
23%. Apart from mortality related to the procedure, safety issues of TAVI also include major non-
fatal complications. Major vascular complications occurred on average in 3.1% of all patients 
included in this review, however, when the TV access route was chosen, the incidence was up to 
33.3% (Table 9). Mean incidence of stroke was 4.4% in TV-TAVI and 1.2% in TA-TAVI patients. 
Atrioventricular block requiring PPM implantation occurred in 9.7% of all TAVI patients, with a 
higher incidence of 12% (range 5%-34.2%) in TV-TAVI patients compared to 6.9% in TA-TAVI 
patients. 
Previous systematic reviews concluded that safety outcomes were likely to improve with accumu-
lating numbers of patients, increasing technical experience, better patient selection and technology 
(Yan, T. D. et al. 2010, van Brabandt, H. and Neyt, M. 2008). Himbert, D. et al. 2009 demonstrated 
procedural success from 84% in the first 25 patients to 98% in the subsequent 50 patients and an 
associated decrease in 30-day mortality from 24% to 4%. Nevertheless, in most recent series pub-
lished in 2010, where improving technical skills and technology performance might have attained 
the flat end on the learning curve, procedure-related 30-day mortality rates remain in the range of 
10% even at very experienced centers (Rodés-Cabau, J. et al. 2010, Walther, T. et al. 2010). 
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These procedure-related mortality rates should be compared with the operative risk patients are 
facing in conventional surgical AVR. However, reliable surgical AVR mortality data is not availa-
ble for presumed target TAVI patients. In a study on patients over ≥75 years with severe AS, 5% 
died during the post-operative period (Iung, B. et al. 2005). In a literature review on results of AVR 
in octogenarians, operative mortality of isolated AVR varied between 4.3% and 10.3% (Iung, B. 
2008). In the series of Kapadia, S. R. et al. 2009, of 92 patients referred for TAVI, approximately 
20% were found to be surgical candidates and underwent surgical AVR without operative deaths 
(only one death at 2 months). However, compared to TAVI patients, surgical AVR patients were 
younger (78±7 versus 81±6 years) and had a lower logistic EuroSCORE (18.3%±8.4% versus 
27.8%±18.8%). Other observations indicated that patients with AS believed inoperable by one 
group of surgeons were considered operable by another (Svensson, L. G. et al. 2008). About half of 
the patients that were referred as potential TAVI candidates were further treated medically, 20% 
were treated with a TAVI with a mortality of 9%, 18% were treated surgically with no mortality at 
all and 11% were treated by means of BAV. In the series of Descoutures, F. et al. 2008, of 66 elder-
ly patients referred for treatment of severe AS, 39 had a calculated operative risk of >20%. Twelve 
patients were treated with TAVI while from the remaining 27 patients, four were redirected towards 
AVR. All of them recovered without adverse events.  
Due to patient safety concerns described above, TAVI is restricted to elderly patients who are con-
sidered at very high risk for surgical AVR (Figulla, H. R. et al. 2009). Accordingly, all included 
studies recruited patients at “high surgical risk” or “nonsurgical candidates”. However, the sur-
gical risk and operability status are not uniformly defined concepts, but are mostly based on a com-
bination of clinical assessment and information from operative risk estimation scores. Most includ-
ed studies, estimated the operative mortality according to the logistic EuroSCORE which has been 
criticized to overestimate the risk, particularly in high-risk patients (Kalavrouziotis, D. et al. 2009, 
Osswald, B. R. et al. 2009, Dewey, T. M. et al. 2008, Brown, M. L. et al. 2008). Rajani, R. et al. 
2010 observed that patients in the medically treated group who had been rejected for TAVI had a 
lower logistic EuroSCORE than those patients who underwent TAVI. This could be interpreted as a 
sign that different criteria are used to identify eligible TAVI patients (e.g. aortic annulus size or iliac 
anatomy). If this assumption proves true, criteria for patient selection should be adapted according-
ly. 
As illustrated by Figure 10, the estimated mortality rates from literature are sharply contrasted by 
the observed mortality rates which are significantly lower, irrespective of the chosen interventional 
approach. In clinical practice, the logistic EuroSCORE is divided by two to approximate the opera-
tive risk in high-risk patients more accurately (Figulla, H. R. et al. 2009) (dotted line in Figure 10). 
It should be noted that a range of significant comorbidities that are often encountered in patients 
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eligible for TAVI are not included in the EuroSCORE scoring method (Rodés-Cabau, J. et al. 2010, 
Al-Attar, N. et al. 2009). From the online calculation tool for the logistic EuroSCORE it can in-
ferred which conditions are not taken into account: heart failure, diabetes mellitus, presence and 
degree of mitral regurgitation, arrhythmias, previous stroke, and renal failure.18 
In a study of 1,177 patients that underwent surgical AVR, the estimated 30-day mortality for the 
highest risk patients was mean 23.6% based on the logistic EuroSCORE. This was sharply con-
trasted by an actual mortality of 5.7% (Brown, M. L. et al. 2008). Whereas the mean logistic Eu-
roSCORE of patients undergoing surgical AVR from the study of Brown and colleagues differed 
only slightly from the mean logistic EuroSCORE calculated in this review for TAVI patients 
(23.6% versus 27.8%), 30-day mortality was substantially lower among surgical AVR patients than 
for TAVI patients (5.7% versus 11.4%). This result might suggest that procedure-related mortality 
in high-risk patients could be lower when they are treated by surgical AVR than if treated by TAVI. 
Only data from an RCT would clarify this. 
The STS score which has been applied in eight included studies, seems to predict the operative risk 
of TAVI patients more precisely (Figure 11). However, particularly for TA patient populations with 
a high actual 30-day mortality, it seems to underestimate the operative risk. Several included stud-
ies (Rodés-Cabau, J. et al. 2010, Webb, J. G. et al. 2009, Himbert, D. et al. 2009) consistently ob-
served that the STS score was unable to identify those patients who would die within 30 days after 
TAVI. 
From the above observations it is clear that one should be cautious to predict operative mortality in 
elderly high-risk patients based on risk scores obtained from historic observational data. Overesti-
mation of risk can lead to denying surgery in patients that may be suitable candidates. In fact, the 
vast majority of patients who underwent TAVI would not have been operated on in the past, and 
therefore, new predictive risk score models including specific variables for this particular subset of 
patients are required in the future. 
 
4.3 Efficacy of TAVI 
In respect to short- to mid-term efficacy, post-TAVI improvements of echocardiographic measure-
ments (AVA, transaortic mean gradient, and LVEF) and NYHA functional class seem encouraging, 
irrespective of the chosen access route. However, long- term outcomes, particularly in respect to 
device durability, are not available yet. At present this might be a less critical issue, given the lim-
                                                     
18 http://www.euroscore.org/calc.html (accessed August 14, 2010). 
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ited life expectancy of eligible TAVI patients, but it might become important in the future, if the 
indication was expanded to broader patient populations. 
Based on the currently available study results described in chapter 3.1.2.5, the improvements of 
echocardiographic measurements after TAVI are stable at 30-day follow-up and sustained until 1-
year follow-up without significant functional deterioration. It is however not clear how this im-
provement can be translated into an improved overall QoL of an elderly and generally frail patient 
population with severe co-morbidities. As of today, no QoL data at 1-year follow-up after TAVI has 
been published. 
A comparison of the evidence on efficacy of TAVI and medical therapy was impeded because none 
of the included studies on medical therapy reported follow-up results on the efficacy of medical 
therapy. 
Neither preceding primary nor secondary publications included in this review provided an econom-
ic evaluation to assess the cost-effectiveness of TAVI. 
 
4.4 Limitations of this work 
The limitations of the results are obvious and should be addressed in future work. Firstly, the find-
ings are based on merely observational studies. Until the data freeze for this work on April 30, 
2010, no RCTs have compared TAVI with surgical AVR, medical treatment or BAV. The publica-
tion of first results from the randomized PARTNER U.S. trial did not occur before September 22, 
2010 (Leon M. B. et al. 2010) and thus, could not be considered as part of the formal information 
synthesis. Apart from the lack of randomization, major shortcomings of the published studies 
which are summarized in this review, are the lack of long-term data, selected and small patient 
groups, and in some cases the involvement of manufacturers. The above discussed inconsistent 
patient selection criteria complicate the interpretation of outcomes from included studies. In addi-
tion, the following significant differences in baseline characteristics – on the one hand, TV-TAVI 
versus TA-TAVI patients and, on the other hand, TAVI versus medically treated patients – should be 
pointed out which might distort the reported results. Comparing TV-TAVI and TA-TAVI patients, 
the pre-procedural transaortic mean gradient reported by all included studies was mean 46.6±15.6 
mmHg with significant difference between TV and TA patients (47.9±17.7 mmHg versus 44.7±16.2 
mmHg) (p-value=0.02). In addition, 51% of TV patients were male compared with only 36% in the 
TA subgroup (p-value<0.0001). For the comparison of TAVI and medically treated patients, includ-
ed studies reported a significantly higher estimated operative risk score as assessed by the logistic 
EuroSCORE for TAVI patients compared to medically treated patients (27.8% versus 13.5%) (p-
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value<0.0001). In addition, the pre-procedural mean AVA of TAVI patients was significantly small-
er than the AVA of medically treated patients (0.63±0.39cm² versus 0.68±0.21cm²) (p-
value<0.0001). Reported differences in other baseline measures were not significant. 
As we were unable to verify to which extent authors had potentially published duplicate trials with 
accumulating numbers of patients or increased lengths of follow-up, all publications meeting our 
inclusion criteria were considered for critical appraisal.19 
 
4.5 Outlook and Conclusion 
Applying a formal methodology used in evidence-based health economics, this review aimed to 
objectively evaluate the safety and efficacy of TAVI, although data from RCT and on long-term 
outcomes were still missing. Based on available data, in patients with inoperable AS, TAVI promis-
es improved 1-year survival when compared with medical treatment. To date, no medical therapy is 
effective for patients with symptomatic severe AS. However, due to patient selection bias, the re-
sults should be interpreted with caution.  
Before the publication of the first RCT data in September 2010 which coincided with the finaliza-
tion of this work, our results represented the best available data set. As the TAVI survival benefit 
elucidated from the systematic literature review is in good congruence with the RCT data, we con-
clude that this methodology represents a powerful tool to confirm - or even anticipate - RCT out-
comes. 
Going forward, future research should address whether the current evidence on safety and efficacy 
of TAVI can be translated into an improved long-term QoL for patients and whether TAVI interven-
tions are effective from an economic point of view.  
                                                     
19 Namely three publications from Canada (Rodés-Cabau, J. et al. 2010, Webb, J. G. et al. 2009, Ye, 
J. et al. 2009)  and two publications from Paris, France (Al-Attar, N. et al. 2009, Himbert, D. et al. 
2009) with overlapping patient enrollment periods bear potential for redundant patient populations. 
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5 Abstract 
Objectives: Transcatheter aortic valve implantation (TAVI) promises effective treatment for high-
risk elderly patients with symptomatic severe aortic stenosis (AS). However, the adoption of TAVI 
must be justified and guarantee long-term performance. Systematic reviews are a core methodology 
in evidence-based health economics for judging medical effectiveness. In this work, the methodol-
ogy was applied to provide objective evidence on the efficacy and safety of TAVI at 1-year follow-
up and to assess whether TAVI confers a survival benefit compared to  medical therapy. 
Methods: In accordance with the toolkit of the “German Scientific Working Group Technology 
Assessment for Health Care” (GSWG), two independent systematic literature reviews on the safety 
and efficacy of TAVI procedures and medical therapy of AS were conducted in major bibliographic 
databases. Preestablished inclusion criteria were defined that were consistent for both reviews. For 
each review, an initial screening of identified articles regarding titles and abstracts was followed by 
a full-text screening. Data from eligible articles was extracted and evaluated according to GSWG 
checklists followed by a qualitative synthesis of information. 
Results: The systematic literature search identified 12 primary publications (derived from 1,849 
citations) for TAVI (number of patients [n]=1,049) and 11 publications (derived from 189 citations) 
for medical therapy of AS (n=946) that fulfilled the inclusion criteria. 
The mean overall procedural success rate for included TAVI interventions was 93.3%. The mean 
combined procedural, post-procedural, and cumulative in-hospital/30-day mortality was 11.4% 
(n=116; range 5.3%–23%). For transvascular (TV) TAVI procedures, the mean inhospital/30-day 
mortality was significantly lower than for transapical (TA) TAVI procedures (9.5% versus 14%) (p-
value=0.03). Major vascular complications occurred on average in 3.1% of all patients included in 
this review, particularly when the TV access route was chosen the incidence was up to 33.3%. 
Mean incidence of stroke was 4.4%. One year after TAVI, the mean overall survival rate was 75.9% 
(range 64.1%–87%) compared with 62.4% (range 40%–84.8%) for medically treated patients (p-
value<0.0001). One-year survival after TAVI for patients treated with TV procedures was signifi-
cantly higher than after TA procedures (79.2% versus 73.6%) (p-value=0.041). At 1-year follow-up, 
the improved valvular function remained stable, and there was a trend towards an improved ven-
tricular function. 
Conclusion: Based on the best available data, in patients with symptomatic severe AS, TAVI 
demonstrates an improved 1-year survival compared with medical treatment. The survival benefit 
of TV-TAVI over medical therapy elucidated from this systematic literature review is +16.8% and 
therefore, in good congruence with the recently published results from the randomized PARTNER 
U.S. trial (+20%). 
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21 Publications excluded from information synthesis which are  not cited in the main document are 
not included in the reference list (bibliography section 6.1). 
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6.3.2 Publications excluded from review on medical therapy of AS22 
Table 2 Study characteristics and rationale for exclusion from review on medical therapy of 
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22 Publications excluded from information synthesis which are  not cited in the main document are 
not included in the reference list (bibliography section 6.1). 
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Natural history of valvular aortic stenosis. Br 
Heart J. 35, 41–46. 
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Table 17: Extracted data from included studies on TAVI 95 
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7.2 Tables 
Table 3: Annual statistics 2008/2009 for aortic valve replacement in Germany (adapted from 
the German Society for Thoracic and Cardiovascular Surgery 2010) 
 2008 2009 Δ
Surgical AVR 12,262 11,457 -6.6%
TAVI  921 2,154 +133.9%
Surgical AVR + Coronary Artery Bypass Grafting (CABG) 8,514 8,005 -6%
Total 21,697 21,616 -0.4%
 
Table 4: Inclusion and exclusion criteria for publications on TAVI 
Characteristic Criteria 
Publication Type Peer-reviewed full-text publications that report clinical outcomes, systematic reviews, and 
publications from health technology institutes. Editorials, laboratory or animal studies 
excluded 
Published (either print or online) by 04/ 2010 
Language English or German 
Intervention Transcatheter aortic valve implantation (TAVI) 
Patient character-
istics 
Patients at risk for surgical AVR with severe AS, excluding asymptomatic patients 
Mean age of study population ≥ 75 years 
Study characteris-
tics 
Clinical studies, excluding case reports 
Patient population larger than n ≥ 10 
Follow-up duration of ≥ 12 postoperative months 
Clinical outcome Safety, efficacy, and/ or cost-effectiveness of TAVI 
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Table 5: Inclusion and exclusion criteria for publications on medical therapy of AS 
Characteristic Criteria 
Publication Type Peer-reviewed full-text publications that report clinical outcomes, systematic reviews, and 
publications from health technology institutes. Editorials, laboratory or animal studies 
excluded 
Published (either print or online) by 04/ 2010 
Language English or German 
Intervention None 
Patient character-
istics 
Patients with severe AS who either refused or were denied surgical AVR, excluding asymp-
tomatic patients 
Mean age of study population ≥ 75 years 
Study characteris-
tics 
Clinical studies, excluding case reports 
Patient population larger than n ≥ 10 
Follow-up duration of ≥ 12 postoperative months 
Clinical outcome Safety, efficacy, and/ or cost-effectiveness of medical treatment of AS 
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Table 6: Study characteristics of included primary publications on TAVI 
Publication Study center Study design Enrollment 
period 
N Valve type 
implanted 
Duration 
follow-up 
(mean; 
months) 
Rodés-Cabau, J. 
et al. 2010 
6 centers, 
Canada 
Prospective, multi-
center study 
01/2005-
06/2009 
33923 (TV 
162 / TA 
177) 
Cribier-
Edwards/ 
Edwards 
Sapien 
8.0* 
Rajani, R. et al. 
2010 
Brighton, 
UK 
Retrospective, 
single-center, 
matched cohort 
study 
12/2007 – 
06/2009 
38 (TV) CoreValve 8.8* 
Walther, T. et al. 
2010 
Leipzig, 
Germany 
Retrospective, 
single-center, 
matched cohort 
study 
10/2006 – 
11/2008 
100 (TA) Edwards 
Sapien 
12.0 
Al-Attar, N. et al. 
2009 
Paris, France Prospective, sin-
gle-center case 
series 
09/2006-
05/2008 
50 (TV 35 / 
TA 15) 
Edwards 
Sapien 
8.6  
Himbert, D. et al. 
2009 
Paris, France Prospective, sin-
gle-center case 
series 
02/2006-
01/2008 
75 (TV 51 / 
TA 24) 
Edwards 
Sapien 
10.0  
Kapadia, S. R. et 
al. 2009 
Cleveland, 
OH, USA 
Prospective, sin-
gle-center, cohort 
study 
02/2006 – 
03/2007 
18 (NA24) Cribier-
Edwards 
9.3  
Thielmann, M. et 
al. 2009 
Essen, Ger-
many 
Prospective, sin-
gle-center case 
series 
05/2007 – 
11/2008 
39 (TV 15 / 
TA 24) 
Cribier-
Edwards/ 
Edwards 
Sapien 
12.0 
Webb, J. G. et al. 
2009 
Vancouver, 
Canada 
Prospective, sin-
gle-center case 
series 
01/2005 -
04/2008 
168 (TV 
113 / TA 
55) 
Cribier-
Edwards/ 
Edwards 
Sapien 
7.4 
                                                     
23 The number of patients was 339, but a total of 345 (TV 168 / TA 177) procedures was performed 
in these patients. 
24 Approach not specified 
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Ye, J. et al. 2009 Vancouver, 
Canada 
Prospective, sin-
gle-center case 
series 
10/2005 -
01/2007 
26 (TA) Edwards 
Sapien 
12.0 
Zierer, A. et al. 
2009 
Frankfurt, 
Germany 
Retrospective, 
single-center, 
matched cohort 
study 
01/2006 – 
04/2007 
21 (TA) Cribier-
Edwards 
12.0 
Grube, E. et al. 
2008 
Siegburg, 
Germany 
Prospective, sin-
gle-center case 
series 
02/2005 – 
03/2008 
136 (TV) CoreValve 12.0 
Otten, A. M. et 
al. 2008 
Rotterdam, 
Netherlands 
Prospective, sin-
gle-center, cohort 
study 
09/2005- 
09/2007 
39 (TA) CoreValve 13.0 
*—median; NA—not available 
 
Table 7:  Demographic and pre-procedural clinical patient characteristics (mean±SD) 
Publication Age (years) 
 
Gender (% 
males) 
Estimated operative risk (%) NYHA classifica-
tion [%(n)] 
Log EuroSCORE STS score 
Rodés-Cabau, J. et 
al. 2010 
81.0±8.0 (TV 
83.0±8.0/TA 
80.0±8.0) 
45 (TV 56/ 
TA 35) 
NA 9.8±6.4(TV 
9±5.8/TA 
10.5±6.9) 
NA 
Rajani, R. et al. 
2010 
83.0* 55 24.0±15.0 NA I. 8% (3) 
II. 29% (11) 
III. 55% (21) 
IV. 8% (3) 
Walther, T. et al. 
2010 
82.7±5.0 23 29.4±13 15.2±8.3 I. 0% (0) 
II. 0% (0) 
III. 76% (76) 
IV. 24% (24) 
Al-Attar, N. et al. 
2009 
83.0±8.0 (TV 
83.0±6.0/TA 
83.0±10.0) 
54 (TV 51/ 
TA 60) 
28.0 ±14.0 (TV 
26.0 ±14.0/ TA 
30.0 ±12.0)  
16.0 ±7.0 (TV 
15.0 ±6.0/ TA 
19.0 ±9.0) 
I. 0% (0) 
II. 6% (3) 
III. 52% (26) 
IV. 42% (21) 
 72 
Himbert, D. et al. 
2009 
82.0±8.0 (TV 
82.0±7.0/TA 
82.0±10.0) 
55 (TV 49/ 
TA 67) 
26.0 ±13.0 (TV 
25.0 ±13.0/ TA 
28.0 ±13.0)  
16.0 ±7.0 (TV 
15.0 ±7.0/ TA 
18.0 ±9.0) 
I. 0% (0) 
II. 5% (4) 
III. 53% (40) 
IV. 41% (31) 
Kapadia, S. R. et 
al. 2009 
81.0±6.0 67 27.8±18.8 11.4±7.5 I. 0% (0) 
II. 0% (0) 
III. 33% (6) 
IV. 67% (12) 
Thielmann, M. et 
al. 2009 
81.4±5 (TV 79.6 
±4.5/TA 82.7±5.1) 
38 (TV 47/ 
TA 33) 
44.2 ±12.6 (TV 
38.1 ±8.1/ TA 
52.5 ±13.4) 
17.9 ±6.1 (TV 
15.1±4.1/ TA 
19.9 ±7.5) 
I. 0% (0) 
II. 5% (2) 
III. 62% (24) 
IV. 33% (13) 
Webb, J. G. et al. 
2009 
84.0* (TV 85.0*/ 
TA 83.0*) 
52 (TV 58/ 
TA 40) 
28.6* (TV 25.0*/ 
TA 35.0*) 
9.1* (TV 8.7*/ 
TA 10.3*) 
I. 1% (2) 
II. 12% (17) 
III. 61% (88) 
IV. 26% (37) 
Ye, J. et al. 2009 80.1±9.1 50 37.0±20.0 11.0±6.0 I. 0% (0) 
II. 19% (5) 
III. 65% (17) 
IV. 16% (4) 
Zierer, A. et al. 
2009 
85.0±6.0 29 38.0 ±14.0 NA 3.4±0.4 
Grube, E. et al. 
2008 
81.5 ±6.9 42 23.1±15 8.9±6.5  3.3±0.5 
Otten, A. M. et al. 
2008 
81±7 46 15.0±6.0  NA NA 
*—median; NA—not available 
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Table 8: Procedural, 30-day, and 1-year primary outcomes after TAVI 
Publication Procedural success rate [% 
(n)] 
30-day mortality rate [% (n)] 1-year survival rate (%) 
Overall TV TA Overall TV TA Overall TV TA 
Rodés-
Cabau, J. et 
al. 2010 
93.3 
(322) 
90.5 
(152) 
96.1 
(170) 
10.4 (36) 9.5 (16) 11.3 (20) 76 75 78 
Rajani, R. 
et al. 2010 
97.3 (37) 97.3 (37) NA 5.3 (2) 5.3 (2) NA 87 87 NA 
Walther, T. 
et al. 2010 
97 (97) NA 97 (97) 10 (10) NA 10 (10) 72 NA 72 
Al-Attar, N. 
et al. 2009 
90 (45) 85.7 (30) 100 (15) 14 (7) 8 (3) 27 (4) 67 74 60 
Himbert, D. 
et al. 2009 
93 (70) 90 (46) 100 (24) 10 (8) 8 (4) 16 (4) 78 81 74 
Kapadia, S. 
R. et al. 
2009 
94 (17) NA NA 5.6 (1) NA NA 78 NA NA 
Thielmann, 
M. et al. 
2009 
97.4 (38) NA NA 17.9 (7) 13.3 (2) 20.8 (5) 64.1 68.1 61.9 
Webb, J. G. 
et al. 2009 
94.1 
(158) 
NA NA 11.3 (19) 8 (9) 18.2 (10) 73.8 NA NA 
Ye, J. et al. 
2009 
100 (26) NA 100 (26) 23 (6) NA 23 (6) 65.4 NA 65.4 
Zierer, A. et 
al. 2009 
100 (21) NA 100 (21) 14 (3) NA 14 (3) 76 NA 76 
Grube, E. et 
al. 2008 
86 (117) 86 (117) NA 12.5 (17) 12.5 (17) NA 81.6 81.6 NA 
Otten, A. 
M. et al. 
2008 
NA NA NA NA NA NA 87 87 NA 
NA—not available 
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Table 9: Procedural and post-procedural complications [% (n)] 25 
Publication Major vascular 
complication 
Cerebrovascular 
accident/ strokes
Myocardial 
infarction 
Cardiac tam-
ponade 
Heart block/ 
PPM require-
ment 
“Valve in 
valve” 
OverallTV TA OverallTV TA OverallTV TA OverallTV TA OverallTV TA OverallTV TA
Rodés-
Cabau, J. et 
al. 2010 
0.6 (2) 
 
1.2 
(2) 
0 
(0) 
2.3 (8) 3.1 
(5) 
1.7 
(3) 
1.2 (4) 0.6 
(1)
1.7 
(3)
0 (0) 0 
(0)
0 
(0) 
4.9 
(17) 
3.7 
(6) 
6.2 
(11) 
2.6 (9) 2.5 
(4)
2.8 
(5)
Rajani, R. et 
al. 2010 
2.6 (1) 2.6 
(1) 
 2.6 (1) 2.6 
(1) 
 0 (0) 0 
(0)
 2.6 (1) 2.6 
(1)
 34.2 
(13) 
34.2 
(13) 
0 (0) 0 
(0)
 
Walther, T. et 
al. 2010 
0 (0)  0 
(0) 
0 (0)  0 (0) 0 (0)  0 
(0)
0 (0)  0 
(0) 
9 (9)*  9 
(9)* 
0 (0)  0 
(0)
Al-Attar, N. 
et al. 2009 
12 (6) 11.4 
(4) 
13.3
(2) 
4 (2) 5.7 
(2) 
0 (0) 0 (0) 0 
(0)
0 
(0)
6 (3) 2.9 
(1)
13.3
(2) 
4 (2) 2.9 
(1) 
6.7 
(1) 
4 (2) 2.9 
(1)
6.7 
(1)
Himbert, D. 
et al. 2009 
10.7 
(8) 
11.8 
(6) 
8.3 
(2) 
4 (3) 5.9 
(3) 
0 (0) 0 (0) 0 
(0)
0 
(0)
5.3 (4) 3.9 
(2)
8.3 
(2) 
5.3 (4) 5.9 
(3) 
4.2 
(1) 
4 (3) 2 
(1)
8.3 
(2)
Kapadia, S. 
R. et al. 2009 
0 (0)   0 (0)   0 (0)   0 (0)   5.6 (1)   0 (0)   
Thielmann, 
M. et al. 
2009 
12.8 
(5) 
33.3
(5) 
0 
(0) 
2.6 (1) 6.7 
(1) 
0 (0) 0 (0) 0 
(0)
0 
(0)
2.6 (1) 6.7 
(1)
0 
(0) 
10.3 
(4) 
26.7 
(4) 
0 
(0) 
2.6 (1) 0 
(0)
4.2 
(1)
Webb, J. G. et 
al. 2009 
6.5 
(11) 
8 
(9) 
3.6 
(2) 
4.2 (7) 5.3 
(6) 
1.8 
(1) 
0 (0) 0 
(0)
0 
(0)
2.4 (4) 1.8 
(2)
3.6 
(2) 
5.4 (9) 4.4 
(5) 
7.3 
(4) 
0 (0) 0 
(0)
0 
(0)
Ye, J. et al. 
2009 
0 (0)  0 
(0) 
3.8 (1)  3.8 
(1) 
3.8 (1)  3.8 
(1)
0 (0)  0 
(0) 
11.5 
(3) 
 11.5 
(3) 
0 (0)  0 
(0)
Zierer, A. et 
al. 2009 
NA  NA NA  NA NA  NANA  NA NA  NA NA  NA
Grube, E. et 
al. 2008 
0 (0) 0 
(0) 
 4.4 (6) 4.4 
(6) 
 2.2 (3) 2.2 
(3)
 1.5 (2) 1.5 
(2)
 25 (34) 25 
(34) 
 2.2 (3) 2.2 
(3)
 
Otten, A. M. 
et al. 2008 
NA NA  NA NA  NA NA NA NA NA NA  NA NA 
NA—not available; *11 of 100 patients already carried a PPM before the TAVI procedure 
                                                     
25 If a publication reported any adverse events, it was assumed that if a type of major complication 
was not mentioned, it would not have occurred. 
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Table 10: Summarized evidence on TAVI efficacy (based on subset of studies reporting baseline, 
30-day, and 1-year follow-up outcomes) 
Patients 
at base-
line 
Reported 
baseline 
Survivors 
at 30-day 
follow up 
Survivors 
at 1-year 
follow up 
Reported 
outcome at 
30-day 
follow-up 
Reported 
outcome at 
1-year 
follow-up 
Consistency 
of results 
Δ between 
baseline 
and 30-day 
follow-up 
Δ be-
tween 30-
day and 
1-year 
follow-up
Mean AVA (cm²) 
282 0.61 247 196 1.65 1.49  +1.04  
(+170.5%) 
-0.16  
(-9.7%) 
Mean transaortic valve gradient (mmHg) 
282 47.6 247 196 10.3 10.1  -37.3  
(-78.4%) 
-0.2  
(-2%) 
Mean LVEF (%) 
240 52.7 205 158 56.2 60.2  +3.5  
(+6.6%) 
+4  
(+7.1%) 
Mean NYHA functional class 
301 3.3 257 210 2 1.8  -1.3  
(-39.4%) 
-0.2  
(-10%) 
NYHA functional class distribution 
165 I. 0% (0) 
II. 4% (7) 
III.71%(117)
IV. 25% (41)
138 99 I. 22% (31)
II. 51% 
(71) 
III. 26% 
(36) 
IV. 0% (0) 
I. 26% (26)
II. 40% 
(39) 
III. 34% 
(34) 
IV. 0% (0) 
 I. +22% 
II. +47% 
III. -45% 
IV. -25% 
I. +4% 
II. -11% 
III. +8% 
IV. ±0% 
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Table 11: Baseline, 30-day, and 1-year secondary outcomes after TAVI (mean± SD) 
Publica-
tion 
Baseline 30-day follow-up 1-year follow-up 
n AVA 
(cm²) 
Mean 
trans-
aortic 
gradient 
(mmHg) 
LVEF 
(%) 
Survi-
vors 
(n) 
AVA 
(cm²) 
Mean 
trans-
aortic 
gradient 
(mmHg)
LVEF 
(%) 
AVA 
(cm²) 
Mean 
trans-
aortic 
gradient 
(mmHg) 
LVEF 
(%) 
Rodés-
Cabau, J. 
et al. 
2010 
339 
(TV 
162 
/ TA 
177) 
0.63±0.1
7 (TV 
0.63±0.1
6/ TA 
0.63±0.1
8) 
46±17 
(TV 
48±18/ 
TA 
44±17) 
55±14 
(TV 
55±14/ 
TA 
56±14) 
303 1.55±0.4
1 
10±4 NA NA NA NA 
Rajani, 
R. et al. 
2010 
38 
(TV
) 
0.66±0.2
0 
56±17 NA 36 NA NA NA NA NA NA 
Walther, 
T. et al. 
2010 
100 
(TA
) 
NA NA 54±15 90 NA NA NA NA NA 58±12 
Al-Attar, 
N. et al. 
2009 
50 
(TV 
35 / 
TA 
15) 
0.61±0.1
6 (TV 
0.60±0.1
6/ TA 
0.63±0.1
7) 
51±14 
(TV 
52±15/ 
TA 
48±12) 
49±15 
(TV 
50±16/ 
TA 
45±13) 
43 1.72±0.4
6 
11±4 NA NA NA NA 
Himbert, 
D. et al. 
2009 
75 
(TV 
51 / 
TA 
24) 
0.64±0.1
6 (TV 
0.63±0.1
6/ TA 
0.65±0.1
7) 
52±15 
(TV 
54±15/ 
TA 
48±14) 
51±15 
(TV 
52±16/ 
TA 
48±13) 
67 1.73±0.4
1 
10±4 58** 1.45** 8** 62** 
Kapadia, 
S. R. et 
al. 2009 
18 
(NA
26) 
0.60±0.1
0 
46±16 46±17 17 NA NA NA NA NA NA 
Thiel-
mann, 
M. et al. 
2009 
39 
(TV 
15 / 
TA 
24) 
0.60 
±0.20 
46±20 51±17 
(TV 
49±21/ 
TA 
52±13) 
32 1.70±0.6
0 
12±5 51±17 1.70±0.6
0 
10±4 59±9 
                                                     
26 Approach not specified 
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Webb, J. 
G. et al. 
2009 
168 
(TV 
113 
/ TA 
55) 
0.60* 
(TV 
0.60*/ 
TA 
0.60*) 
46* (TV 
48*/ TA 
41*) 
NA 149 1.60±0.4
0 
10±4 NA 1.50±0.3
0 
11±5 NA 
Ye, J. et 
al. 2009 
26 
(TA
) 
0.50±0.1
0 
45±14 56 ±13 20 NA NA 59±5 1.70±0.5
0 
9±5 63±9 
Zierer, 
A. et al. 
2009 
21 
(TA
) 
NA NA NA 18 NA NA NA 1.50±0.8
0 
10±4 NA 
Grube, 
E. et al. 
2008 
136 
(TV
) 
0.67 
±0.9 
42±17 51±17 119 NA NA NA NA 8±4 NA 
Otten, A. 
M. et al. 
2008 
39 
(TV
) 
NA NA NA NA NA NA NA NA NA NA 
*—median; **—mean; NA—not available 
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Table 12: Potential overlaps of included references (or related previous publications27) and pub-
lished systematic reviews/ HTA reports 
Publication Study cen-
ter 
Enrollment 
period 
N References in published systematic reviews/ HTA reports 
van Bra-
bandt, H. 
and Neyt, 
M. 2009 
(KCE 
Belgium)
Yan, T. D. 
et al. 2010 
2009 
(Sydney, 
Australia) 
van 
Bra-
bandt, H. 
and 
Neyt, M. 
2008 
(KCE 
Belgium)
NICE 
2008 
(UK)
Blan-
chard, S. 
2008 
(Haute 
Autorité 
de Santé 
(HAS) 
France) 
Wild, C. 
et al. 
2008 
(LBI 
Austria) 
Wild, C. 
and 
Geiger-
Gritsch, 
S. 2009 
(LBI 
Austria)
Rodés-
Cabau, J. et 
al. 2010 
6 centers, 
Canada 
01/2005-
06/2009 
339Webb, J. G. et al. 2007 (n=50); enrollment 
01/2005 – NA 
Lichtenstein, S. V. et al. 2006 (n=7); enrollment 
10/2005 – NA 
Ye, J. et al. 2007 (n=7); enrollment 10/2005 – 
NA 
  
Rajani, R. 
et al. 2010 
Brighton, 
UK 
12/2007 – 
06/2009 
38        
Walther, T. 
et al. 2010 
Leipzig, 
Germany 
02/2006-
01/2008 
100Walther, T. et al. 2008 (n=50); enrollment 
02/2006-03/2007 
Walther, T. et al. 2007b (n=59); enrollment 
02/2006 - 10/2006 
Walther, T. et al. 2007a (n=30); enrollment 
02/2006 - 09/2006 
  
Al-Attar, N. 
et al. 2009 
Paris, 
France 
09/2006-
05/2008 
50 Descoutures, F. et al. 
2008 (n=12); 
enrollment 10/2006 – 
04/2007 
     
Himbert, D. 
et al. 2009 
Paris, 
France 
10/2006 – 
11/2008 
75      
Kapadia, S. 
R. et al. 
2009 
Cleveland, 
OH, USA 
02/2006 – 
03/2007 
18        
                                                     
27 Related publications were defined as duplicate publications from the same centers with overlap-
ping enrollment period and accumulating number of patients, or increased length of follow-up. 
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Thielmann, 
M. et al. 
2009 
Essen, 
Germany 
05/2007 – 
11/2008 
39        
Webb, J. G. 
et al. 2009 
Vancouver, 
Canada 
01/2005 -
04/2008 
168  Included    
Ye, J. et al. 
2009 
Vancouver, 
Canada 
10/2005 -
01/2007 
26 Webb, J. G. et al. 2007 (n=50); enrollment 
01/2005 – NA 
Lichtenstein, S. V. et al. 2006 (n=7); enrollment 
10/2005 – NA 
Ye, J. et al. 2007 (n=7); enrollment 10/2005 – 
NA 
  
Zierer, A. et 
al. 2009 
Frankfurt, 
Germany 
01/2006 – 
04/2007 
21 Zierer, A. et al. 2008 
(n=26); enrollment 
02/2006 – 02/2008 
     
Grube, E. et 
al. 2008 
Siegburg, 
Germany 
02/2005 – 
03/2008 
136Grube, E. et al. 2006 (n=25); enrollment 02/2005 -
11/2005 
Grube, E. et al. 2007 (n=86); enrollment 08/2005 - 
02/2007 
Included
Otten, A. 
M. et al. 
2008 
Rotterdam, 
Netherlands
09/2005- 
09/2007 
39       Included 
NA—not available 
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Table 13: References of earlier systematic reviews/ HTAs which were already described by van 
Brabandt, H. and Neyt, M. 2008 
Publication Study center Approach N References in 2008 systematic reviews/ 
HTAs 
KCE 
Belgium 
NICE UK HAS 
France 
LBI Aus-
tria 
Cribier, A. et 
al. 2004 
Rouen, 
France 
TV/ antegrade 
(Edwards) 
6 X X X X 
Cribier, A. et 
al. 2006 
Rouen, 
France 
TV/ antegrade 
(Edwards) 
36 X X X X 
Webb, J. G. et 
al. 2007 
Vancouver, 
Canada 
TV (Edwards) 50 X X X X 
Lichtenstein, 
S. V. et al. 
2006 
Vancouver, 
Canada 
TA (Edwards) 7 X X X X 
Ye, J. et al. 
2007 
Vancouver, 
Canada 
TA (Edwards) 7 X X X  
Walther, T. et 
al. 2007a 
Leipzig, 
Germany 
TA (Edwards) 30 X X X  
Walther, T. et 
al. 2007b 
Multicenter, 
Germany 
TA (Edwards) 59 X X X  
Svensson, L. 
G. et al. 2008 
Multicenter, 
US 
TA (Edwards) 40 X    
Grube, E. et al. 
2006 
Siegburg, 
Germany 
TV 
(CoreValve) 
35 X X X X 
Grube, E. et al. 
2007 
Multicenter, 
Germany/ 
Canada 
TV 
(CoreValve) 
86 X X X X 
Marcheix, B. 
et al. 2007 
Montreal, 
Canada 
TV 
(CoreValve) 
10 X   X 
Berry, C. et al. 
2007 
Montreal, 
Canada 
TV 
(CoreValve) 
11 X X X X 
X—reference included 
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Table 14: Key results of earlier systematic reviews/ HTAs 
Outcome 
parameter 
Access 
Route 
 2008 systematic reviews/ HTAs (n=included patients) 
KCE Belgium  
(n=423) 
NICE UK 
(n=336) 
HAS France 
(n=47028) 
LBI Austria  
(n=257) 
Procedural 
Success rate 
(%) 
TV  68-93 75-88 NA 74-100 
TA  71-93 93-100 NA NA 
30-day mor-
tality (%) 
TV  6-13 12-22 NA 11-50 
TA  8-23 10-14 NA NA 
6-months 
survival (%) 
TV  78-90 41-81 71-84 57 
TA  55-74 NA 68 NA 
30-day pro-
cedural and 
post-
procedural 
complications 
(%) 
TV  Vascular complica-
tions 10-15,  
Stroke 3-10 
Stroke 2-12,      
Bradyarrhythmia 
36,                   
Major bleeding 18, 
Cardiac            
tamponade 10,        
Vascular injuries 5, 
Access-site     
infection 5 
NA NA 
TA  NA Pleural effusion 
31-37,            
Stroke 3,   Hemo-
filtration 14,    
Tracheotomy 14, 
Rethoracotomy 14
NA NA 
AVA (cm²) TV Pre-
TAVI 
0.5-0.7 0.6 0.6 0.5-0.7 
Post-
TAVI 
1.6-1.7 1.3-1.9 1.7 1-2 
TA Pre-
TAVI 
0.6-0.7 0.7 0.6 NA 
Post-
TAVI 
1.6-1.8 1.8 1.4 NA 
                                                     
28 Including approximately 135 patients from presented series 
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Transaortic 
mean gradi-
ent (mmHg) 
TV Pre-
TAVI 
37-46 37-51 45 31-51 
Post-
TAVI 
9-11 9-11 10 6-13 
TA Pre-
TAVI 
NA 32-43 46 NA 
Post-
TAVI 
NA 8-11 9 NA 
Economic 
evaluation 
Cost assess-
ment 
NA NA NA  High-level cost 
estimate of 2,400 € 
per intervention 
excluding associat-
ed personnel, other 
operating expense, 
and hospital stay. 
Estimated 
number of 
eligible TAVI 
patients per 
year 
135-290 in Bel-
gium (population 
~10.4 million)29 
NA Minimum 600 in 
France (population 
~61.3 million)30 
Approximately 30 
in Upper Austria 
(population ~1.4 
million)31 
Recommendation on reim-
bursement 
NA NA Conditional reim-
bursement for 
high-risk patients 
NA 
NA—not available 
                                                     
29 Source: www.who.int/countries  
30 Source: www.who.int/countries  
31 Source: http://de.wikipedia.org/wiki/Oberösterreich#Bev.C3.B6lkerung 
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Table 15: Study characteristics of included studies on medical therapy 
Publication Study center Study design Enrollment 
period 
N Treatment 
groups for 
comparison 
Mean fol-
low-up 
(months) 
Bakaeen, F. G. et 
al. 2010 
Houston, TX, 
USA 
Retrospective, 
single-center, 
cohort study 
01/1997–
04/2008 
140 (M) Surgical AVR 
(n=205) 
NA 
Rajani, R. et al. 
2010 
Brighton, UK Retrospective, 
single-center 
cohort study 
12/2007–
06/2009 
47 (M 
33 / 
M+BA
V 14) 
TAVI (n=38), 
BAV (n=14) 
7.2*  
Bach, D. S. et al. 
2009 
Ann Arbor, 
MI, USA 
Retrospective, 
multi-center 
cohort study 
01/2005–
12/2005 
126 (M) Asymptomatic 
AS (n=65), 
surgical AVR 
(n=205) 
16.7 
Kapadia, S. R. et 
al. 2009 
Cleveland, 
OH, USA 
Prospective, 
single-center 
cohort study 
02/2006–
03/2007 
36 (M) TAVI (n=18), 
surgical AVR 
(n=19), BAV, 
n=19) 
6.0 
van Geldorp, M. 
W. A. et al. 2009 
Rotterdam, 
Netherlands 
Retrospective, 
multi-center 
cohort study 
10/2004–
12/2007 
101 (M) Surgical AVR 
(n=76) 
15.1 
Kojodjojo, P. et al. 
2008 
Hertfordshire, 
UK 
Retrospective, 
multi-center 
cohort study 
01/2001–
12/2006 
86 (M) Surgical AVR 
(n=15) 
19.2 
Otten, A. M. et al. 
2008 
Rotterdam, 
Netherlands 
Prospective, 
single-center 
cohort study 
09/2005–
09/2007 
16 (M) TAVI (n=39), 
surgical AVR 
(n=14), BAV 
(n=3) 
11.0 
Charlson, E. et al. 
2006 
Boston, MA, 
USA 
Retrospective, 
multi-center 
cohort study 
01/1995–
12/1997 
75 (M) Surgical AVR 
(n=49) 
NA 
Varadarajan, P. et 
al. 2006b 
Los Angeles, 
CA, USA 
Retrospective, 
single-center 
cohort study 
01/1993–
12/2003 
197 (M) Surgical AVR 
(n=80) 
30.0 
Iung, B. et al. 
2005 
Paris, France Prospective, 
multi-center 
cohort study 
04/2001–
07/2001 
72 (M) Surgical AVR 
(n=144) 
NA 
O'Keefe, J. H., JR 
et al. 1987 
Rochester, 
MN, USA 
Retrospective, 
single-center case 
series 
01/1978–
12/1985 
50 (M) None 20.1 
*—median; NA—not available; M—medical therapy 
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Table 16: Demographic and pre-procedural clinical and echocardiographic patient characteristics 
(mean±SD) 
Publication N Age 
(years) 
Gender 
(% 
males) 
Estimated operative 
risk (%) 
NYHA clas-
sification 
[%(n)] 
Degree of AS 
log Eu-
roSCORE 
STS 
score 
AVA (cm²) Transaortic 
mean gradi-
ent (mmHg) 
LVEF (%)
Bakaeen, F. 
G. et al. 2010 
140 75.7±8.6 NA 9.0±2.0 NA NA NA NA 42±15 
Rajani, R. et 
al. 2010 
47 81.0* 48 13.0** NA I. 17% (8) 
II. 30% (14) 
III. 49% (23)
IV. 4% (2) 
0.71±0.23 45±20 NA 
Bach, D. S. 
et al. 2009 
126 75.0±12.5 62 NA 3.8* NA NA NA NA 
Kapadia, S. 
R. et al. 2009 
36 83.0±8.0 47 25.4±17.6 12.6±9.2I. 0% (0) 
II. 0% (0) 
III. 53% (19)
IV. 47% (17)
0.70±0.20 41±17 48±16 
van Geldorp, 
M. W. A. et 
al. 2009 
101 73.3±12.3 51 11.3±9.6 NA 2.5** 0.71±0.26 NA NA 
Kojodjojo, P. 
et al. 2008 
86 86.2* 37 16.8±12.2 NA NA 0.65±0.21 NA 61** 
Otten, A. M. 
et al. 2008 
16 82.0±14.0 38 25.0±14.0 NA NA NA NA NA 
Charlson, E. 
et al. 2006 
75 81.5±8.3 29 NA NA NA NA NA NA 
Varadarajan, 
P. et al. 
2006b 
197 85.3±4.1 42 NA NA NA 0.68±0.16 39±15 NA 
Iung, B. et 
al. 2005 
72 81.7±4.6 43 NA NA NA 0.73±0.23 52±20 52±18 
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O'Keefe, J. 
H., JR et al. 
1987 
50 77.0** 72 NA NA NA 0.57** NA NA 
*—median; **—mean; NA—not available 
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7.4 Figures 
Figure 1: Schematic decision-making process for TAVI patient evaluation a 
Patients with symptomatic, severe AS
Assessment for surgical AVR
Low risk a:
Log EuroSCORE ≤ 20%
STS score ≤ 10% 
Age < 75 years
High risk a:
Log EuroSCORE > 20%
STS score > 10%
Age ≥ 75 years
or contraindications to surgery
Surgical AVR Assessment for TV-TAVI
No contraindication
Contraindications to TV access 
route, e. g. unsuited vascular 
access, calcified aortic arch or 
descending aorta
TV-TAVI Assessment for TA-TAVI
No contraindication
Contraindication to TA 
access route
TA-TAVI Medical therapy and/ or BAV  
a  Risk classification according to German Society of Cardiology (DGK) positioning statement 
(Figulla, H. R. et al. 2009) 
 
Figure 2: Flow chart literature search results for review on TAVI a  
1,590 citations excluded based on 
screening of titles and abstracts
1,849 citations identified from
literature search and screened (excluding 
duplicates)
259 potentially relevant reports retrieved 
for scrutiny (full text, if available)
10 potentially relevant reports retrieved 
from database alerts (6) and cross-
references (4)
38 reports excluded based on evaluation 
of extracted data:
 no relevant clinical outcomes/ missing 
follow-up (37)
 published later than April 30, 2010 (1)
19a relevant publications included for 
literature review (thereof 12 primary and 7 
systematic reviews/ publications from 
HTA institutes)
212 reports excluded based on full text 
screening
57 potentially relevant reports included 
for data extraction 
 
a  Three cohort studies (Rajani, R. et al. 2010, Kapadia, S. R. et al. 2009, Otten, A. M. et al. 2008) 
were also included for the information synthesis on medical therapy of AS. 
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Figure 3: Mean inhospital/ 30-day mortality rates (from literature) and approximated 95%-CI a, b  
Grube et al. (TV/ 
n=136)
Rajani et al. (TV/ n=38)
Thielmann et al. (TV/ 
n=15; TA/ n=24)
Zierer et al. (TA/ n=21)
Ye et al. (TA/ n=26)
Walther et al. (TA/ 
n=100)
Kapadia et al. (NA/ 
n=18)
Himbert et al. (TV/ 
n=51; TA/ n=24)
Webb et al. (TV/ n=113; 
TA/ n=55)
Rodés-Cabau et al. (TV/ 
n=162; TA/ n=177)
Al-Attar (TV/ n=35; TA/ 
n=15)
-10 0 10 20 30 40
Inhospital/ 30-day mortality (%)
2010
2009
2008
95%-CI:
Bubbles: Transvascular 
(TV)
Transapical (TA) Total
 
a  The area of bubbles represents the number of included patients (n). 
b  Particularly in small patient populations, the applied approximation method for 95%-CI can 
return negative lower boundaries. In these cases, the lower boundary of the 95%-CI was re-
stricted to 0. 
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Figure 4: Mean 1-year survival rates (from literature) and approximated 95%-CIa  
Grube et al. (TV/ n=136)
Otten et al. (TV/ n=39)
Rajani et al. (TV/ n=38)
Ye et al. (TA/ n=26)
Thielmann et al. (TV/ 
n=15; TA/ n=24)
Zierer et al. (TA/ n=21)
Al-Attar et al. (TV/ 
n=35; TA/ n=15)
Walther et al. (TA/ 
n=100)
Himbert et al. (TV/ 
n=51; TA/ n=24)
Webb et al. (TV/ n=113; 
TA/ n=55)
Rodés-Cabau et al. (TV/ 
n=162; TA/ n=177)
Kapadia et al. (n=18)
20 30 40 50 60 70 80 90 100
1-year survival rate (%)
2010
2009
2008
95%-CI:
Bubbles: Transvascular 
(TV)
Transapical (TA) Total
 
a  The area of bubbles represents the number of included patients (n).
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Figure 5: Improvement of AVA and transaortic mean gradient after TAVI (based on those studies 
reporting baseline, 30-day, and 1-year follow-up outcomes) 
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Figure 6: NYHA functional class improvement after TAVI (based on subset of studies reporting 
baseline, 30-day, and 1-year follow-up outcomes) 
 
NYHA functional 
class
IV
III
II
I
1 year30 daysBaseline
0%
34%
39%
26%
0%
26%
51%
23%
25%
71%
4%
0%
Time after 
intervention
1 year30 daysBaseline
1.8±0.4
1.9±0.3
3.3±0.6
n=301 n=210n=255n=165 n=99n=138
Distribution per NYHA classa Mean NYHA classb
 
a  Based on (Walther, T. et al. 2010, Thielmann, M. et al. 2009, Ye, J. et al. 2009)  
b  Based on (Walther, T. et al. 2010, Thielmann, M. et al. 2009, Ye, J. et al. 2009, Grube, E. et al. 
2008) 
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Figure 7: Flow chart literature search results for review on medical therapy of AS 
169 citations excluded based on 
screening of titles and abstracts
189 citations identified from
electronic search and screened 
(excluding duplicates)
31 potentially relevant reports retrieved 
for scrutiny (full text, if available)
11 potentially relevant reports retrieved 
from database alerts (5) and cross-
references (6)
20 reports excluded based on detailed 
evaluation:
 no relevant clinical outcomes/ missing 
follow-up (7)
 population inappropriate (13)
11 relevant reports for literature review  
 
 
Figure 8: Mean 1-year survival rates (from literature) and approximated 95%-CI for medical 
treatment of AS a 
Iung et al. 84.8% 
(n=72)
Varadarajan et al. 52% 
(n=197)
Charlson et al. 54.7% 
(n=75)
Otten et al. 40% (n=16)
Kojodjojo et al. 55.2% 
(n=86)
Van Geldorp et al. 77% 
(n=101)
Kapadia et al. 58% 
(n=36)
Bach et al. 66.5% 
(n=126)
Rajani et al. 64% 
(n=47)
Bakaeen et al. 65% 
(n=140)
0 10 20 30 40 50 60 70 80 90 100
Survival Rate at 1 year (%)
 
a  The area of bubbles represents the number of included patients (n). 
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Figure 9: 1-year survival rates resulting from information synthesis and approximated 95%-CI 
after TAVI or with medical treatment a 
Medical therapy 
(n=946)
Total TAVI (n=1.049)
thereof TA-TAVI (n=442)
thereof TV-TAVI (n=589)
40 50 60 70 80 90 100
1-year survival rate (%)
75.9 [73.3-78.4]
73.6 [69.2-77.9]
79.2 [75.5-82.8]
62.4 [59.3-65.5]
Mean survival rates (%) [95%-CI]
 
a  The area of bubbles represents the number of included patients (n). 
b  An overview of included publications on TAVI is provided in the bibliograhy (6.2.1) 
c  An overview of included publications on medical therapy is provided in the bibliograhy (6.2.3) 
c 
b 
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Figure 10: Estimated operative risk (EuroSCORE) versus observed 30-day mortality rates a 
Grube et al.
Webb et al. 
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Ye et al.
Webb et al. 
Thielmann et al.
Himbert et al.
Al-Attar et al.
Walther et al.
Kapadia et al
0
10
20
30
40
50
0 10 20 30
30-day mortality (%)
Es
tim
at
ed
 o
pe
ra
tiv
e 
ris
k 
(lo
g 
Eu
ro
SC
O
RE
)
Overest imated R isk 
(mortality < log EuroSCORE)
Underest imated R isk 
(mortality > log EuroSCORE)Overest imated R isk 
(mortality < (1/2) *log 
EuroSCORE)
Underest imated R isk 
(mortality > (1/2) *log 
EuroSCORE)
Linear 
Equation
Bubbles: Transvascular (TV) Transapical (TA) NA
mortality = log EuroSCORE mortality = (1/2) * log EUROSCORE
 
a  The area of bubbles represents the number of included patients (n). 
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Figure 11: Estimated operative risk (STS score) versus observed 30-day mortality ratesa 
Himbert et al. Thielmann et al.
Webb et al. 
Grube et al.
Rodes-Cabau et al.
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a  The area of bubbles represents the number of included patients (n). 
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7.5 Templates results section  
7.5.1 Data extraction template TAVI 
Table 17: Extracted data from included studies on TAVI 
Study characteristics
Number of patients
Enrollment 
period Study center Study design Valve type
Mean duration 
follow-up 
(months)
Total TV TV Total SD
Rodés-Cabau, J. et al. 2010 339 162 177
01/2005-
06/2009
6 centers, 
Canada
prospective, multi-
center study
Cribier-Edwards/ 
Edwards Sapien 8.0* 
Rajani, R. et al. 2010 38 38
12/2007-
06/2009 Brighton, UK
retrospective, single-
center, matched cohort 
study CoreValve 8.8* 
Walther, T. et al. 2010 100 100
02/2006-
01/2008
Leipzig, 
Germany
retrospective, single-
center, matched cohort 
study Edwards Sapien 12.0    
Al-Attar, N. et al. 2009 50 35 15
09/2006-
05/2008 Paris, France
prospective, single-
center cohort study Edwards Sapien 8.6    5.6 
Himbert, D. et al. 2009 75 51 24
10/2006-
11/2008 Paris, France
prospective, single-
center case series Edwards Sapien 10.0    6.0 
Kapadia, S. R. et al. 2009 18
02/2006-
03/2007
Cleveland, 
USA
prospective, single-
center cohort study Cribier-Edwards 9.3    4.3 
Thielmann, M. et al. 2009 39 15 24
05/2007-
11/2008
Essen, 
Germany
prospective, single-
center case series
Cribier-Edwards/ 
Edwards Sapien 12.0    
Webb, J. G. et al. 2009 168 113 55
01/2005-
04/2008
Vancouver, 
Canada
prospective, single-
center case series
Cribier-Edwards/ 
Edwards Sapien 7.4    
Ye, J. et al. 2009 26 26
10/2005-
01/2007
Vancouver, 
Canada
prospective, single-
center case series Edwards Sapien 12.0    
Zierer, A. et al. 2009 21 21
01/2006-
04/2007
Frankfurt, 
Germany
retrospective, single-
center, matched cohort 
study Cribier-Edwards 12.0    4.0 
Grube, E. et al. 2008 136 136
02/2005-
03/2008
Siegburg, 
Germany
prospective, single-
center case series CoreValve 12.0    
Otten, A. M. et al. 2008 39 39
09/2005-
09/2007
Rotterdam, 
Netherlands
prospective, single-
center cohort study CoreValve 13.0    7.0 
Publication
 
*—median 
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7.5.2 Data extraction template medical therapy 
Table 18: Extracted data from included studies on medical therapy of AS 
Study characteristics
Mean duration 
follow-up (months)
Total SD
Bakaeen, F. G. et al. 2010 140
01/1997-
04/2008 Houston, TX, USA
retrospective, single-
center, cohort study
medical therapy (n=140)/ 
surgical AVR (n=205)
71% 
symptomatic
Rajani, R. et al. 2010 47
12/2007-
06/2009 Brighton, UK
retrospective, single-
center, matched 
cohort study
medical therapy (n=33)/ 
medical therapy + BAV 
(n=14)/ TAVi (n=38) symptomatic 7.2* 
Bach, D. S. et al. 2009 126
01/2005-
12/2005
Ann Arbour, MI, 
USA
retrospective, multi-
center cohort study
medical therapy (n=126 
symptomatic; n=65 
asymptomatic)/ surgical 
AVR (n=205) symptomatic 16.7    14.1 
Kapadia, S. R. et al. 2009 36
02/2006-
03/2007
Cleveland, OH, 
USA
prospective, single-
center cohort study
medical therapy (n=36)/ 
TAVI (n=18)/ surgical 
AVR (n=19)/ BAV (n=19) symptomatic 6.0    3.5 
van Geldorp, M. W. A. et al. 2009 101
10/2004-
12/2007 Netherlands
retrospective, multi-
center cohort study
medical therapy (n=101)/ 
surgical AVR (n=76) symptomatic 15.1    11.5 
Kojodjojo, P. et al. 2008 86
01/2001-
12/2006 Hertfordshire, UK
retrospective, multi-
center cohort study
medical therapy (n=86)/ 
surgical AVR (n=15) symptomatic 19.2    16.8 
Otten, A. M. et al. 2008 16
09/2005-
09/2007
Rotterdam, 
Netherlands
prospective, single-
center cohort study
medical therapy (n=16)/ 
TAVI (n=39)/ surgical 
AVR (n=14)/ BAV (n=3)
81% 
symptomatic 11.0    7.0 
Charlson, E. et al. 2006 75
01/1995-
12/1997 Boston, MA, USA
retrospective, multi-
center cohort study
medical therapy (n=75)/ 
AVR (n=49) symptomatic
Varadarajan, P. et al. 2006b 197
01/1993-
12/2003
Los Angeles, CA, 
USA
retrospective, single-
center cohort study
medical therapy (n=197)/ 
AVR (n=80) symptomatic 30.0    
Iung, B. et al. 2005 72
04/2001-
07/2001 Paris, France
prospective, multi-
center cohort study
medical therapy (n=72)/ 
AVR (n=144) symptomatic
O'Keefe, J. H., JR et al. 1987 50
01/1978-
12/1985
Rochester, MN, 
USA
retrospective, single-
center case series medical therapy (n=50) symptomatic 20.1    
Publication
Number of 
patients Intervention
Enrollment 
period Study center Study design
Symptomatic 
status
 
*—median 
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7.6 Literature search strategy 
The following search strategies were used to identify papers on TAVI and medical therapy of AS in 
MEDLINE. A similar strategy was used to identify papers in other databases. 
TAVI 
#1  ("aortic stenosis"[MeSH Terms] OR "aortic valve stenosis”) AND (“heart valve prosthe-
sis"[MeSH Terms] OR “heart valve prosthesis implantation"[MeSH Terms] OR "valve replace-
ment" OR "valve implantation" OR "aortic valve/surgery"[MeSH Terms] OR "aortic valve steno-
sis/surgery"[MeSH Terms]) 
#2  (#1) AND (“percutaneous" OR “transcatheter" OR “transvascular” OR “transapical” OR 
“transfemoral" OR “transluminal" OR “transaortic" OR "CoreValve" OR "Edwards Sapien" OR 
"Cribier") 
#3  (#2) AND "humans"[MeSH Terms] AND (English[lang] OR German[lang]) AND 
("adult"[MeSH Terms: noexp] OR "middle aged"[MeSH Terms] OR "aged"[MeSH Terms] OR 
"aged, 80 and over"[MeSH Terms]) 
 
Medical therapy of AS 
#1  ("aortic stenosis"[MeSH Terms] OR "aortic valve stenosis”) AND (“natural history” OR 
“natural course” OR (("medical" OR “conservative”) AND (“therapy” OR “treatment” OR “man-
agement”)) 
#2  (#1) AND "humans"[MeSH Terms] AND (English[lang] OR German[lang]) AND 
("adult"[MeSH Terms] OR "middle aged"[MeSH Terms] OR "aged"[MeSH Terms] OR "aged, 80 
and over"[MeSH Terms]) 
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7.7 Evaluation of study quality 
7.7.1 Primary publications included for review on TAVI 
Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.1.1 
Title: Transcatheter Aortic Valve Implantation for the Treatment of Severe Symptomatic Aortic Stenosis in Patients at Very High or
Prohibitive Surgical Risk: Acute and Late Outcomes of the Multicenter Canadian Experience 
Authors: Rodés-Cabau, J. et al. 2010 
Source: J Am Coll Cardiol. 2010; 55: 1080–1090 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 Case series:  Other:      
Clas A Selection of study participants Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
  B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
    a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
    a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
Q B 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
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QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?       
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.1.2 
Title: Prognostic benefit of transcatheter aortic valve implantation compared with medical therapy in patients with inoperable aortic
stenosis 
Authors: Rajani, R. et al. 2010 
Source: Catheter Cardiovasc Interv. 2010;75:1121–1126 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants  Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?    
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?    
QA 3. Has the disease status been assessed in a valid and reliable manner?    
QBI 4. Are the diagnostic criteria of the disease described?    
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
   
QA 6. For cohort studies: Were the study groups considered simultaneously?    
  7. Has the determination of the sample size been specified?    
 8. Are the period of recruitment and follow-up indicated?    
  B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?    
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
    a) with respect to demographic characteristics    
  b) with respect to clinical characteristics    
QB 3. Was the selection conducted randomized with a standard procedure?    
  a) was the allocation sequence generated by an accepted procedure?    
  b) was the allocation sequence concealed until the intervention?    
QC 4. Was the randomization blinded?    
  a) for the patient    
  b) for the intervening physician    
QA 5. Were known / possible confounders taken into account at the start of the study?    
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?    
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?    
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?    
QA 4. For RCTs: Have placebos been used for the control groups?    
QA 5. For RCTs: has the administration of placebos been documented?    
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?    
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
   
QA 3. Was it ensured that study participants did not change between intervention and control groups?    
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?    
QA 2. Were the outcomes recorded in a valid and reliable manner?    
Q B 3. Was the outcome measurement blinded?    
QC 4. In case series: was the distribution of prognostic factors adequately covered?    
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a suffi-
ciently large part of the cohort be followed-up over the entire study period? 
   
QA 2. Were the reasons for the drop-outs of study participants listed?    
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?    
QB 4. If differences were found - are they significant?    
QB 5. If differences were found - are they relevant?    
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?    
  2. For RCT: was an intention-to-treat analysis conducted?    
    a) Were all randomized individuals analyzed within the group to which they were assigned?    
    b) Were deviations of the non-randomized cases reported that were included in the analysis?    
    c) Has the effect of missing values been analyzed?    
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
   
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
   
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?    
  H Discussion Yes No ? 
  1. Are the following point in respect to the interpretation of results sufficiently covered?       
    a) the reference to the study hypothesis    
    b) the sources of distortion    
    c) statistical uncertainties     
    d) hazard multiple testing     
  2.  Was the external validity (generalizability) of the study results discussed?    
  3.  Were the study results discussed in the context of current evidence?    
Final assessment: This publication is 
included              excluded     
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Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.1.3 
Title: Transapical aortic valve implantation in 100 consecutive patients: comparison to propensity-matched conventional aortic valve
replacement 
Authors: Walther, T. et al. 2010 
Source: Eur H J 2010;31:1398-1403 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants  Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
    a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
Q B 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.1.4 
Title: Transcatheter aortic valve implantation: Selection strategy is crucial for outcome 
Authors: Al-Attar, N. et al. 2009 
Source: Ann Thorac Surg 2009;87:1757-1763 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants  Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
QB 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.1.5 
Title: Results of transfemoral and transapical aortic valve implantation following a uniform assessment in high-risk patients with aortic
stenosis 
Authors: Himbert, D. et al. 2009 
Source: JACC 2009;54:303-311 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants  Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
QB 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.1.6 
Title: Characterization and outcome of patients with severe symptomatic aortic stenosis referred for percutaneous aortic valve replace-
ment 
Authors: Kapadia, S. R. et al. 2009 
Source: J Thorac Cardiovasc Surg 2009;137:1430-1435 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants  Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
QB 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.1.7 
Title: Transcatheter aortic valve implantation in patients with very high risk for conventional aortic valve replacement 
Authors: Thielmann, M. et al. 2009 
Source: Ann Thorac Surg 2009;88:1468-1475 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 Case series:  Other:      
Clas A Selection of study participants Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
QB 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.1.8 
Title: Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes 
Authors: Webb, J. G. et al. 2009 
Source: Circulation 2009;119:3009-3016 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
QB 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.1.9 
Title: Transapical transcatheter aortic valve implantation: 1-year outcome in 26 patients 
Authors: Ye, J. et al. 2009 
Source: J Thorac Cardiovasc Surg 2009;137:167-173 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 Case series:  Other:      
Clas A Selection of study participants Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
QB 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.1.10 
Title: Is transapical aortic valve implantation really less invasive than minimally invasive aortic valve replacement? 
Authors: Zierer, A. et al. 2009 
Source: J Thorac Cardiovasc Surg 2009;138:1067-1072 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
QB 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.1.11 
Title: Progress and current status of percutaneous aortic valve replacement: results of three device generations of the CoreValve Re-
valving system 
Authors: Grube, E. et al. 2008 
Source: Circ Cardiovasc Intervent 2008;1:167-175 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
QB 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.1.12 
Title: Population characteristics, treatment assignment and survival of patients with aortic stenosis referred for percutaneous valve re-
placement 
Authors: Otten, A. M. et al. 2008 
Source: EuroIntervent 2008;4:250-255 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?    
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?    
QA 3. Has the disease status been assessed in a valid and reliable manner?    
QBI 4. Are the diagnostic criteria of the disease described?    
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
   
QA 6. For cohort studies: Were the study groups considered simultaneously?    
  7. Has the determination of the sample size been specified?    
 8. Are the period of recruitment and follow-up indicated?    
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?    
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics    
  b) with respect to clinical characteristics    
QB 3. Was the selection conducted randomized with a standard procedure?    
  a) was the allocation sequence generated by an accepted procedure?    
  b) was the allocation sequence concealed until the intervention?    
QC 4. Was the randomization blinded?    
  a) for the patient    
  b) for the intervening physician    
QA 5. Were known / possible confounders taken into account at the start of the study?    
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?    
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?    
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?    
QA 4. For RCTs: Have placebos been used for the control groups?    
QA 5. For RCTs: has the administration of placebos been documented?    
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?    
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
   
QA 3. Was it ensured that study participants did not change between intervention and control groups?    
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?    
QA 2. Were the outcomes recorded in a valid and reliable manner?    
QB 3. Was the outcome measurement blinded?    
QC 4. In case series: was the distribution of prognostic factors adequately covered?    
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a suffi-
ciently large part of the cohort be followed-up over the entire study period? 
   
QA 2. Were the reasons for the drop-outs of study participants listed?    
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?    
QB 4. If differences were found - are they significant?    
QB 5. If differences were found - are they relevant?    
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?    
  2. For RCT: was an intention-to-treat analysis conducted?    
    a) Were all randomized individuals analyzed within the group to which they were assigned?    
    b) Were deviations of the non-randomized cases reported that were included in the analysis?    
    c) Has the effect of missing values been analyzed?    
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
   
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
   
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?    
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis    
    b) the sources of distortion    
    c) statistical uncertainties     
    d) hazard multiple testing     
  2.  Was the external validity (generalizability) of the study results discussed?    
  3.  Were the study results discussed in the context of current evidence?    
Final assessment: This publication is 
included              excluded     
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7.7.2 Primary publications included for review on medical therapy of AS 
Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.2.1 
Title: Severe aortic stenosis in a veteran population: treatment considerations and survival 
Authors: Bakaeen, F. G. et al. 2010 
Source: Ann Thorac Surg 2010;89:453-458 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
    a) for the patient   
    b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
Q B 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
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QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following point in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.2.2 
Title: Prognostic benefit of transcatheter aortic valve implantation compared with medical therapy in patients with inoperable aortic
stenosis 
Authors: Rajani, R. et al. 2010 
Source: Catheter Cardiovasc Interv. 2010;75:1121–1126 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants  Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
Q B 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following point in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.2.3 
Title: Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement 
Authors: Bach, D. S. et al. 2009 
Source: Circ Cardiovasc Qual Outcomes 2009;2:533-539 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants  Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
Q B 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.2.4 
Title: Therapeutic decisions for patients with symptomatic severe aortic stenosis: room for improvement? 
Authors: van Geldorp, M. W. A. et al. 2009 
Source: Eur J Cardiothorac Surg 2009;35:953-959 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants  Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?    
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?    
QA 3. Has the disease status been assessed in a valid and reliable manner?    
QBI 4. Are the diagnostic criteria of the disease described?    
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
   
QA 6. For cohort studies: Were the study groups considered simultaneously?    
  7. Has the determination of the sample size been specified?    
 8. Are the period of recruitment and follow-up indicated?    
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?    
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics    
  b) with respect to clinical characteristics    
QB 3. Was the selection conducted randomized with a standard procedure?    
  a) was the allocation sequence generated by an accepted procedure?    
  b) was the allocation sequence concealed until the intervention?    
QC 4. Was the randomization blinded?    
  a) for the patient    
  b) for the intervening physician    
QA 5. Were known / possible confounders taken into account at the start of the study?    
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?    
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?    
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?    
QA 4. For RCTs: Have placebos been used for the control groups?    
QA 5. For RCTs: has the administration of placebos been documented?    
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?    
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
   
QA 3. Was it ensured that study participants did not change between intervention and control groups?    
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?    
QA 2. Were the outcomes recorded in a valid and reliable manner?    
Q B 3. Was the outcome measurement blinded?    
QC 4. In case series: was the distribution of prognostic factors adequately covered?    
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a suffi-
ciently large part of the cohort be followed-up over the entire study period? 
   
QA 2. Were the reasons for the drop-outs of study participants listed?    
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?    
QB 4. If differences were found - are they significant?    
QB 5. If differences were found - are they relevant?    
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?    
  2. For RCT: was an intention-to-treat analysis conducted?    
    a) Were all randomized individuals analyzed within the group to which they were assigned?    
    b) Were deviations of the non-randomized cases reported that were included in the analysis?    
    c) Has the effect of missing values been analyzed?    
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
   
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
   
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?    
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis    
    b) the sources of distortion    
    c) statistical uncertainties     
    d) hazard multiple testing     
  2.  Was the external validity (generalizability) of the study results discussed?    
  3.  Were the study results discussed in the context of current evidence?    
Final assessment: This publication is 
included              excluded     
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 Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.2.5 
Title: Characterization and outcome of patients with severe symptomatic aortic stenosis referred for percutaneous aortic valve replace-
ment 
Authors: Kapadia, S. R. et al. 2009 
Source: J Thorac Cardiovasc Surg 2009;137:1430-1435 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants  Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
QB 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.2.6 
Title: Outcomes of patients aged 80 and over with symptomatic, severe aortic stenosis: impact of patients’ choice of refusing aortic valve
replacement on survival 
Authors: Kojodjojo, P. et al. 2008 
Source: QJM 2008;101:567-573 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?    
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?    
QA 3. Has the disease status been assessed in a valid and reliable manner?    
QBI 4. Are the diagnostic criteria of the disease described?    
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
   
QA 6. For cohort studies: Were the study groups considered simultaneously?    
  7. Has the determination of the sample size been specified?    
 8. Are the period of recruitment and follow-up indicated?    
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?    
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics    
  b) with respect to clinical characteristics    
QB 3. Was the selection conducted randomized with a standard procedure?    
  a) was the allocation sequence generated by an accepted procedure?    
  b) was the allocation sequence concealed until the intervention?    
QC 4. Was the randomization blinded?    
  a) for the patient    
  b) for the intervening physician    
QA 5. Were known / possible confounders taken into account at the start of the study?    
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?    
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?    
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?    
QA 4. For RCTs: Have placebos been used for the control groups?    
QA 5. For RCTs: has the administration of placebos been documented?    
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?    
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
   
QA 3. Was it ensured that study participants did not change between intervention and control groups?    
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?    
QA 2. Were the outcomes recorded in a valid and reliable manner?    
QB 3. Was the outcome measurement blinded?    
QC 4. In case series: was the distribution of prognostic factors adequately covered?    
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a suffi-
ciently large part of the cohort be followed-up over the entire study period? 
   
QA 2. Were the reasons for the drop-outs of study participants listed?    
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?    
QB 4. If differences were found - are they significant?    
QB 5. If differences were found - are they relevant?    
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?    
  2. For RCT: was an intention-to-treat analysis conducted?    
    a) Were all randomized individuals analyzed within the group to which they were assigned?    
    b) Were deviations of the non-randomized cases reported that were included in the analysis?    
    c) Has the effect of missing values been analyzed?    
 140 
QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
   
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
   
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?    
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis    
    b) the sources of distortion    
    c) statistical uncertainties     
    d) hazard multiple testing     
  2.  Was the external validity (generalizability) of the study results discussed?    
  3.  Were the study results discussed in the context of current evidence?    
Final assessment: This publication is 
included              excluded     
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Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.2.7 
Title: Population characteristics, treatment assignment and survival of patients with aortic stenosis referred for percutaneous valve re-
placement 
Authors: Otten, A. M. et al. 2008 
Source: EuroIntervent 2008;4:250-255 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?    
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?    
QA 3. Has the disease status been assessed in a valid and reliable manner?    
QBI 4. Are the diagnostic criteria of the disease described?    
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
   
QA 6. For cohort studies: Were the study groups considered simultaneously?    
  7. Has the determination of the sample size been specified?    
 8. Are the period of recruitment and follow-up indicated?    
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?    
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics    
  b) with respect to clinical characteristics    
QB 3. Was the selection conducted randomized with a standard procedure?    
  a) was the allocation sequence generated by an accepted procedure?    
  b) was the allocation sequence concealed until the intervention?    
QC 4. Was the randomization blinded?    
  a) for the patient    
  b) for the intervening physician    
QA 5. Were known / possible confounders taken into account at the start of the study?    
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?    
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?    
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?    
QA 4. For RCTs: Have placebos been used for the control groups?    
QA 5. For RCTs: has the administration of placebos been documented?    
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?    
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
   
QA 3. Was it ensured that study participants did not change between intervention and control groups?    
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?    
QA 2. Were the outcomes recorded in a valid and reliable manner?    
QB 3. Was the outcome measurement blinded?    
QC 4. In case series: was the distribution of prognostic factors adequately covered?    
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a suffi-
ciently large part of the cohort be followed-up over the entire study period? 
   
QA 2. Were the reasons for the drop-outs of study participants listed?    
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?    
QB 4. If differences were found - are they significant?    
QB 5. If differences were found - are they relevant?    
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?    
  2. For RCT: was an intention-to-treat analysis conducted?    
    a) Were all randomized individuals analyzed within the group to which they were assigned?    
    b) Were deviations of the non-randomized cases reported that were included in the analysis?    
    c) Has the effect of missing values been analyzed?    
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
   
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
   
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?    
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis    
    b) the sources of distortion    
    c) statistical uncertainties     
    d) hazard multiple testing     
  2.  Was the external validity (generalizability) of the study results discussed?    
  3.  Were the study results discussed in the context of current evidence?    
Final assessment: This publication is 
included              excluded     
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Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.2.8 
Title: Decision-making and outcomes in severe symptomatic aortic stenosis 
Authors: Charlson, E. et al. 2006 
Source: J Heart Valve Dis 2006;15:312-321 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants  Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
QB 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.2.9 
Title: Survival in elderly patients with severe aortic stenosis is dramatically improved by aortic valve replacement: results from a cohort
of 277 patients aged ≥80 years 
Authors: Varadarajan, P. et al. 2006b 
Source: Eur J Cardiothorac Surg 2006;30:722-727 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants  Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
QB 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.2.10 
Title: Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? 
Authors: Iung, B. et al. 2005 
Source: Eur Heart J 2005;26:2714-2720 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants  Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
 C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
 D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
 E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
QB 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
 F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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Checklist 2a 
Checklist 2a: Primary studies (RCTs / case-control studies / cohort studies / longitudinal studies / case series) 
Report No.: 9.5.1.2.11 
Title: Natural history of candidates for balloon aortic valvuloplasty 
Authors: O'Keefe, J. H., JR et al. 1987 
Source: Mayo Clin Proc 1987;62:986-991 
Document 
type 
RCT:  Cohort study:  Case-control study:  Longitudinal 
study: 
 
 Case series:  Other:      
Clas A Selection of study participants  Yes No ? 
QA 1. Are the inclusion and exclusion criteria for study participants sufficiently / clearly defined?   
QA 2. Have the inclusion and exclusion criteria been defined before the intervention?   
QA 3. Has the disease status been assessed in a valid and reliable manner?   
QBI 4. Are the diagnostic criteria of the disease described?   
QB 5. Is the study population / exposed population representative of the majority of the exposed population or 
the "standard users" of the intervention? 
  
QA 6. For cohort studies: Were the study groups considered simultaneously?   
  7. Has the determination of the sample size been specified?   
 8. Are the period of recruitment and follow-up indicated?   
 B Assignment and study participation Yes No ? 
QA 1. Do the exposed / cases and non-exposed/ controls come from a similar population?   
QA 2. Are the intervention/ exposed group and the control/ non-exposed group comparable at baseline?    
  a) with respect to demographic characteristics   
  b) with respect to clinical characteristics   
QB 3. Was the selection conducted randomized with a standard procedure?   
  a) was the allocation sequence generated by an accepted procedure?   
  b) was the allocation sequence concealed until the intervention?   
QC 4. Was the randomization blinded?   
  a) for the patient   
  b) for the intervening physician   
QA 5. Were known / possible confounders taken into account at the start of the study?   
  C Intervention / Exposure Yes No ? 
QA 1. Were intervention or exposure recorded in a valid, reliable and similar manner?   
QB 2. Were the intervention / control groups - with the exception of the intervention - treated alike?   
QB 3. In case of different therapies, have they been recorded in a valid and reliable manner?   
QA 4. For RCTs: Have placebos been used for the control groups?   
QA 5. For RCTs: has the administration of placebos been documented?   
  D Study Administration Yes No ? 
QB 1. Is there evidence of an "Overmatching"?   
QB 2. In multicenter studies: were the diagnostic and therapeutic methods, and the outcome measurement 
identical in all participating centers? 
  
QA 3. Was it ensured that study participants did not change between intervention and control groups?   
  E Outcome measurement Yes No ? 
I 1. Were point-of-care outcome parameters used?   
QA 2. Were the outcomes recorded in a valid and reliable manner?   
QB 3. Was the outcome measurement blinded?   
QC 4. In case series: was the distribution of prognostic factors adequately covered?   
  F Drop Outs Yes No ? 
QA 1. Was the response rate in intervention / control groups high enough or in cohort studies: could a sufficient-
ly large part of the cohort be followed-up over the entire study period? 
  
QA 2. Were the reasons for the drop-outs of study participants listed?   
QB 3. Were the outcomes of the drop-outs described and considered in the evaluation?   
QB 4. If differences were found - are they significant?   
QB 5. If differences were found - are they relevant?   
  G Statistical analysis Yes No ? 
QA 1. Are the described analytical procedures correct and is that information sufficient for a proper evaluation?   
  2. For RCT: was an intention-to-treat analysis conducted?   
    a) Were all randomized individuals analyzed within the group to which they were assigned?   
    b) Were deviations of the non-randomized cases reported that were included in the analysis?   
    c) Has the effect of missing values been analyzed?   
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QB 3. Have the effect estimates and their precision (e.g. confidence intervals) been reported for all primary and 
secondary outcomes for each group?  
  
  4. Has the distinction between a priori defined analysis and exploratory analysis been made and was the 
problem of multiple testing of hypotheses considered? 
  
I 5. Are the results presented in a graphical form and are the underlying values for the graphics expressed?   
  H Discussion Yes No ? 
  1. Are the following points in respect to the interpretation of results sufficiently covered?    
    a) the reference to the study hypothesis   
    b) the sources of distortion   
    c) statistical uncertainties    
    d) hazard multiple testing    
  2.  Was the external validity (generalizability) of the study results discussed?   
  3.  Were the study results discussed in the context of current evidence?   
Final assessment: This publication is 
included              excluded     
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7.7.3 Secondary publications on TAVI 
Checklist 1a 
Checklist 1a: context documents/ HTA 
Report no.: 9.5.2.6             
Title: Percutaneous heart valve implantation in congenital and degenerative valve disease. A rapid health technology assessment. 
Author: van Brabandt, H. and Neyt, M. 2008 
Source: Online publication (Belgian KCE): http://www.kce.fgov.be/index_en.aspx?SGREF=5212&CREF=12220 
Document type: HTA report                guideline                other document   
Target recipients: decision makers               clinicians               patients               other  
Clas A Research question and context Yes No ? 
I 1. Are the motive and objections of the publication presented in terms of a "policy question"?  
   
QA 2. Is the research question for the intervention (of interest) precisely formulated within a broad-
er context? 
 
   
I 3. Does the publication include information on the following aspects:  
I   a) epidemiology of the target disease    
I   b) (development) state of technology    
I   c) efficacy    
I   d) effectiveness    
I   e) side effects    
I   f) indications    
I   g) contraindications    
I   h) practice variation    
I   i) supply structures    
I   j) cost considerations    
I   k) socio-economic, ethical and legal impact    
Clas B. Methods of information gathering  Yes No ? 
QA 1. Are the sources used documented?    
QB 2. Are the search strategies documented?    
QB 3. Are the inclusion criteria defined?    
QB 4. Are the exclusion criteria defined?    
Klas C Methods of evaluation and documentation Yes No ? 
QA 1. Are validity criteria taken into account?    
QC 2. Was the assessment conducted independently by several people?    
QC 3. Are excluded studies documented with their reasons for exclusion?    
QC 4. Is the data extraction documented in a comprehensive manner?    
QC 5. Was the data extraction conducted by several people independently?    
Clas D Methods of information synthesis Yes No ? 
I   Quantitative information syntheses (please fill out the included checklist 1b on meta-
analysis). 
   
I   Qualitative information syntheses (please fill out the included checklist 1b on information 
synthesis) 
   
I   Were proprietary surveys conducted to complement the available data?    
Clas E Results / Conclusions Yes No ? 
QB 1. Is the existing evidence consistently transferred into the conclusions?    
QA 2. Are methodological limitations of the evidence critically discussed?    
I 3. Are recommendations for action provided?    
I 4. Is there a grading of the recommendation?    
QC 5. Did the publication undergo an external review process before being published?    
I 6 Is a future update of the publication planned?    
Clas F Transferability of international/ foreign results and conclusions Yes No ? 
    Do differences exist in respect to the:   
    a) epidemiology of the target condition?    
    b) development state of the technology?    
    c) indication?    
    d) health care contexts, conditions, processes?    
    e) compensation schemes?    
    f) socio-economic consequences?    
    g) patient and provider preferences?    
Final assessment: This publication is: included               excluded   
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Checklist 1b 
Checklist 1b: systematic reviews and meta-analyses 
Report no.: 9.5.2.1              
Title: Transcatheter aortic valve implantation for high-risk patients with severe aortic stenosis: A systematic review 
Authors: Yan, T. D. et al. 2010 
Source: J Thorac Cardiovasc Surg, 139:1519-1528 
This document contains: 
qualitative information synthesis  
 
quantiative information synthesis  
Clas A Research question Yes No ? 
QA 1. Is the research question relevant to your own question?    
Clas B information retrieval Yes No ? 
  1. Documentation of the literature search:       
QA a) have the sources used been documented?    
QB b) have the search strategies been documented?    
QB 2. Were the inclusion criteria define?    
QB 3. Were the exclusion criteria defined?    
  C Evaluation of information Yes No ? 
  1. Documentation of the study evaluation:       
QA a) Have criteria of validity been taken into account?    
QB b) Was the evaluation conducted independently by several people?    
QC c) Were excluded studies documented with their reasons for exclusion?    
QC 2. Is the documentation of data extraction comprehensible?    
QC 3. Was the data extraction conducted independently by several people?    
  D Information synthesis Yes No ? 
  1. Quantitative Information synthesis:    
QA a) Was the method for the meta-analysis specified?     
QB b) Were heterogeneity tests conducted?    
QC c) Were the results examined for robustness in a sensitivity analysis?    
  2. Qualitative information syntheses:       
QA a) Is the synthesis of information clearly documented?    
QB b) Is there an evaluation of existing evidence?    
  E Conclusions Yes No ? 
QB 1. Is the research question answered?    
QB 2. Is the existing evidence consistently transferred into the conclusions?    
QA 3. Are methodological limitations related to the significance of results critically discussed?    
I 4. Are recommendations for action provided?    
I 5. Is there a grading of the recommendations?    
I 5. Are further research needs identified?    
I 6. Is a future update of the review planned?    
  F Transferability of international/ foreign results and conclusions Yes No ? 
  Do differences exist in respect to the:       
  a) epidemiology of the target condition?    
  b) development state of the technology?    
  c) indication?    
  d) health care contexts, -environment, -processes?    
  e) compensation schemes?    
  f) socio-economic consequences?    
  g) patient and provider preferences?    
Final assessment: This publication is 
included              excluded     
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Checklist 1b 
Checklist 1b: systematic reviews and meta-analyses 
Report no.: 9.5.2.2 
Title: Safety of percutaneous aortic valve insertion. A systematic review 
Authors: van Brabandt, H. and Neyt, M. 2009 
Source: BMC Cardiovasc Disord 9: 45-51 
This document contains: 
qualitative information synthesis  
 
quantiative information synthesis  
Clas A Research question Yes No ? 
QA 1. Is the research question relevant to your own question?    
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8 Table of abbreviations 
 
ACC American College of Cardiology 
ACE Angiotension-converting enzymes 
AHA American Heart Association 
AI Aortic insufficiency 
AR Aortic regurgitation 
AS Aortic stenosis 
AVA Aortic valve area 
AVR Aortic valve replacement 
BAV Balloon aortic valvuloplasty 
CABG Coronary Artery Bypass Grafting 
CDSR Cochrane Database of Systematic Reviews 
CI Confidence interval 
cm² Square centimeter 
CRD Center for Reviews and Dissemination 
DGK German Society of Cardiology 
DGTHG German Society for Thoracic and Cardiovascular Surgery  
ESC European Society of Cardiology 
EQ-5DTM Trademark of the EuroQoL Group (Descriptive system of health-related 
quality of life states consisting of 5 dimensions (mobility, self-care, usual 
activities, pain/discomfort, anxiety/depression)) 
EU European Union 
EuroSCORE European System for Cardiac Operative Risk Evaluation 
e.g. exempli gratia (for example) 
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et al. Et alii (and other [team members]) 
GSWG German Scientific Working Group Technology Assessments for Health 
Care 
HAS Haute Autorité de Santé (France) 
HTA Health Technology Assessment 
ICU Intensive care unit 
i.e. id est (that is) 
INAHTA International Network of Agencies for Health Technology Assessment 
IQWiG Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Germa-
ny) 
KCE Health Care Knowledge Center (Belgium) 
LBI Ludwig-Bolzmann-Institut (Austria) 
LVEF Left ventricular ejection fraction 
M Medical therapy 
m² Square meter 
MACCE Major adverse cardiac and cerebrovascular events 
MeSH Medical Subject Headings 
MI Myocardial infarction 
mmHg Millimeters of mercury 
N/ n Number of patients 
NA Not available 
NICE National Institute for Health and Clinical Excellence (UK) 
NYHA New York Heart Association 
PARTNER Placement of Aortic Transcatheter Valves Trial 
PPM Permanent pacemaker 
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QoL Quality of Life 
RCT Randomized controlled trial 
SD Standard deviation 
STS Society of Thoracic Surgeons 
TAVI Transcatheter aortic valve implantation 
TA Transapical 
TV Transvascular 
UK United Kingdom 
USA United States of America 
www World wide web 
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